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ABSTRACT 
 
 
 
Antiproliferative effects of Garcinia fruits in breast cancer 
cells by 
Harini Anandhi Senthilkumar 
 
 
 
Advisor: Dr. Edward J. Kennelly 
 
 
 
Breast cancer continues to be the second leading cause of death in women, even with the 
recent advances in research that has led to an improved understanding of molecular pathways 
and targets. Increasing mortality due to recurrence and lack of targeted drugs, especially in 
aggressive breast cancer subtypes such as triple negative breast cancer, has gained attention 
from the research community. With nearly 50% of the commonly used cancer drugs being 
sourced from plants, bioactive small molecules derived from a natural origin have immense 
potential as therapeutics. This study focuses on the anti-proliferative activities of 
benzophenones isolated from the edible fruits of Garcinia xanthochymus and Garcinia 
paucinervis in breast cancer cells, particularly triple negative breast cancer cells. Novel 
benzophenones paucinones E – I from Garcinia paucinervis were tested on a panel of breast 
cancer cell lines MDA-MB-231, MCF-7 and SKBR-3 with varying receptor statuses. 
Paucinone H was active across the panel of cell lines studied, with IC50 values ranging from 
10 to 20 µM. Since the activity was significant on MDA- MB-231, the possible pathways in 
MDA-MB-231 that paucinone H could modulate were 
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investigated. Paucinone H induced apoptosis in a dose dependent fashion at IC50 
concentration and decreased mitosis and migration at half IC50 concentration in MDA-MB-
231. 
In addition to the research described above, a comprehensive review of dietary phytoestrogens 
and their impact on breast pathophysiology is also presented in Chapter 2. Appendices A and 
B discuss the use of UPLC-QTOF-MS based metabolomics to verify bioactivities of various 
vegetative organs of Garcinia oblongiflia and the identification of novel benzophenones from 
Garcinia paucinervis 
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 Garcinia belongs to the family Clusiaceae with more than 450 species, widely distributed 
over tropical Asia, Africa, Madagascar, North East Australia and Polynesia (J. Bennett and Lee 
1989). About 30 species are endemic to India while about 20 have been identified to be endemic 
to China (Kumar et al., 2013). One among the well-studied Garcinia species that is endemic to 
India is Garcinia Indica (Kokum), known for the presence of HCA (hydroxy citric acid) which is 
a popular ingredient in weight loss supplements (Chuah et al., 2013). Polyphenols from Garcinia 
occur in vegetative organs of these plants, such as their fruits, leaves, stem and bark and their use 
has been reported in Ayurveda, traditional Chinese medicine and Brazilian and Thai folk 
medicine (Obolskiy et al., 2009; Hemshekhar et al., 2011). Their medicinal applications vary 
from the use of fruit infusions to treat skin ailments such as rashes and burns to their use in 
treatment of peptic ulcer and urinary diseases (Corrêa and Pena 1984). The two primary 
Garcinia species, that are the focus of this study are Garcinia xanthochymus and Garcinia 
paucinervis.  
Garcinia xanthochymus is native to India. The fruit is used in preserves, jams, curries and 
in the preparation of dyes. The dried fruit sap is called gamboge. Fruits of Garcinia 
xanthochymus are pale orange to dark yellow in color and measure about 9 cm in diameter. 
Usually, each fruit has about 2 to 3 seeds (Baggett et al., 2005; Staples and Herbst 2005). The 
fruits have an acidic taste and strong flavor, while the seeds are bitter. In some cultures, seeds are 
used in a concoction to treat diarrhea (Barukial and Sarmah 2011). Garcinia paucinervis is a 
timber species that occurs in limestone mountains in the South East Yunnan and Guangxi 
provinces in China (Xi-wen Li 1998). Due to its economic importance, overharvesting has led 
this species to be classified as endangered (Class II). Several vegetative organs such as roots, 
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leaves, bark and wood of Garcinia paucinervis are known to be used in folk medicine as an 
antidote to treat skin infections, burns and bruises (Fan 2012). 
Some of the popular bioactive compounds from Garcinia xanthochymus that have been reported 
for their cytotoxic/anti-proliferative activity are: xanthochymol, isoxanthochymol, 
cycloxanthochymol, gambogic acid and gambogenone (Protiva et al., 2008). These compounds 
have shown the ability to modulate multiple signaling pathways ranging from mTOR, 
PI3K/AKT  to inhibition of HAT (histone acetylase transferase) (Einbond et al., 2013).   
                                       
Figure 1: Garcinia paucinervis fruits                           Figure 2: Garcinia xanthochymus fruits 
 
 
Figure 3: Freeze-dried Garcinia xanthochymus fruits, dissected to show seeds 
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1.1 Garcinia xanthochymus & Garcinia paucinervis fruits – Phytochemistry  
Phytochemistry of Garcinia species 
Three major classes of polyphenols occur in Garcinia species. They are benzophenones, 
biflavonoids and xanthones. Several studies have reported the bioactivity of these compounds 
such as ability to increase expression of bax, suppression of bcl-2 and cell proliferation, 
induction of apoptosis by increased expression of caspase 3 (Guruvayoorappan and Kuttan 2008; 
Chantarasriwong et al., 2009; Batova et al., 2010). Among these classes, xanthones and 
benzophenones have received attention for a wide range of biological activities (Genovese et al., 
2016). With more than 300 candidates reported to date, the unique chemistry of benzophenones 
is a major reason for the research community’s attention (Wu et al., 2014). Varying levels of 
benzophenones produced by members of Garcinia indicates their possible use as chemo 
systematic markers in addition to their significant role as major components of floral resins 
(Anholeti et al., 2015).  
Structurally, benzophenones have a phenol-carbonyl-phenol skeleton as shown in (Fig 4). 
The A ring is a benzene ring (derived from shikimate pathway) while the B ring derived from the 
malonate pathway undergoes prenylation and cyclization to give rise to a variety of structurally 
unique compounds with bi, tri and tetra cyclic ring systems (Baggett et al. 2005).  
 
Figure 4: 13-carbon skeleton of a benzophenone with A and B rings 
A B 
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 Prenylated benzophenones could further be divided into: Basic benzophenones and 
Polyprenylated benzophenones (PPBs) (J. Bennett and Lee 1989). Basic benzophenones are 
characterized by a thirteen carbon skeleton, with complete A and B rings and varying -OH, 
prenyl or geranyl groups that are uncyclized or have not undergone more than one cyclization 
(Wu et al. 2014). Polyprenylated benzophenones (PPBs) on the other hand, have a complete A 
ring and their variety is introduced as a result of varying additional groups attached to the B ring. 
PPBs are subdivided into types A, B, C or D depending on the location at which the benzoyl 
group is linked. As of 2013, a total of 80 PPBs have been reported from Garcinia spp with 
guttiferone being the largest class of PPBs with 22 subtypes (Kumar et al. 2013). 
Polyisoprenylated benzophenones from Garcinia xanthochymus that were used in this study are 
xanthochymol and guttiferone E (Fig 5). Both belong to Type B PPBs. 
 
 
 
Figure 5: Bioactive benzophenones from Garcinia xanthochymus – xanthochymol, guttiferone E 
and garcinol (Baggett et al. 2005) 
Garcinol  
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Results of our previous studies, showed that location and arrangement of the prenyl side chains 
caused a significant difference in the cytotoxicity of these benzophenones (Baggett et al. 2005). 
Additionally, guttiferone E has a double bond between C32 and C33 whereas, xanthochymol has a 
double bond between C33 and C34 (Acuna et al., 2010). This could also explain the reason for 
guttiferone E being more bioactive than its isomer xanthochymol (Protiva et al. 2008). In another 
study, the ability of xanthochymol to cause caspase 3 induced apoptosis in human leukemia cell 
lines was attributed to the presence of 1,3, diketone and a phenolic ring (Matsumoto et al., 2003). 
The importance of lipophilic, catechol and enol functional groups was also revealed in a study in 
which both xanthochymol and guttiferone E as a mixture were tested for their ability to inhibit 
microtubule disassembly (Roux et al., 2000).  
 
A list of studies that were conducted within the last 12 years, on benzophenones from Garcinia 
spp. on cancer cell lines and the pathways studied are shown in Table 1. Listed in the order of 
their publication year, we have included only studies that utilize pure benzophenones and not 
fruit extracts. Synergistic studies that involve pure compounds and one or more extracts have 
also been excluded. Structures of the most reported compounds (garcinol, xanthochymol and 
guttiferone E) are listed in Figure 5. 
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Compound (s) Cell line (s) 
Concentration 
used 
Targeted 
Pathway(s) 
Reference 
Garcinol A-549, H-460, H-
1299, H-1650, H-
358, and HCC-827
2 μM Downregulation of  
Aldehyde 
Dehydrogenase 1 
Family Member A1 
(Wang et 
al., 2017) 
Guttiferone K HCC 20 μM Cell migration and 
invasion 
(Shen et al., 
2016) 
Garcinol SCC-4, SCC-9 and 
SCC-25 
5, 10 and 15 μM Anti-proliferative, 
pro-apoptotic, cell-
cycle regulatory and 
anti-angiogenic  
(Aggarwal 
and Das 
2016) 
Epigarcinol & 
Isogarcinol 
HL-60 &PC-3 4 and 76 µg/mL Cell cycle arrest 
(G2/S) and 
antiproliferative 
(Pieme et 
al., 2015) 
Guttiferone K HCT-116 3.4 µmol/L Caspase 3 induced 
apoptosis 
(Li et al., 
2017) 
Garcinol MCF-7 35 μmol/L Down regulation of 
Cyclin D,Bcl-2 and 
Bcl-xl 
(Ye et al., 
2014) 
Garcinol H-1299, H-460 10 μM Decrease of CDK 2,4 
and 6, p38 MAPK 
signaling 
(Yu et al., 
2014) 
Guttiferone K HT-29, CCD-841 
CoN 
5.39 ± 0.22  μM Cell cycle, Cyclin 
D1, D3, CDK 4&6 
and caspase 3 
induced apoptosis 
(Kan et al., 
2013) 
Guttiferone E HCT-116, CCRF-
CEM, MDA-MB-
231BCRP 
13.92  μM Activation of 
Caspases 3, 7, 8 and 
9, Alteration of 
Mitochondrial 
Membrane potential 
(Kuete et 
al., 2013) 
Guttiferone E, 
Guttiferone H and 
Xanthochymol 
HCT-116, HT-29, 
SW-480 
Gut E- 9-17  μM 
Xanthochymol 
10-17  μM
Cell cycle arrest at 
IC50, Caspase 
activation at IC50*2, 
mTor 
(Protiva et 
al. 2008) 
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Compound (s) Cell line (s) 
Concentration 
used 
Targeted 
Pathway(s) 
Reference 
 
Guttiferone E and 
Xanthochymol (Pure 
compounds and 
synergy with Sulindac) 
 
HT-29 Colon 
cancer cells 
 
4 μg/ml 
Combinatorial effects 
with sulindac sulfide, 
rapamycin, turmeric 
and celecoxib  
(Einbond et 
al. 2013) 
Garcinol  CAL27 25 μmol/L  Inhibition of STAT-3 
activation, Inhibition 
of NFĸβ 
(Li et al., 
2013) 
Garcinol  MDA-MB-231 
and BT-549 
25 μmol/L  Reversal of EMT, 
Inhibition of 
NFĸβ,vimentin & 
nuclear β-catenin 
(Ahmad et 
al., 2012b) 
Garcinol MDA-MB-231 25 μM STAT-3 
phosphorylation, 
Reduction in 
invasion and 
migration 
(Cheng et 
al., 2010; 
Ahmad et 
al., 2012a) 
Garcinol LNCaP, C4-2B 
and PC3 and 
BxPC-3 
18 μM Cell proliferation, 
apoptosis and 
downregulation of 
NFĸβ 
(Ahmad et 
al., 2011) 
Garcinol BxPC-3 and Panc-
1 
20 μM Anti-angiogenic, 
anti-metastatic and 
anti-proliferative 
(Parasramka 
and Gupta 
2011) 
 
Guttiferone A and K 
 
HCT-116, HT-29, 
SW-480 
Between 10- 25 
µM (including all 
the 3 cell lines) 
Cytotoxicity (Yang et al., 
2010) 
Garcinol Hep3B  20 μM ER stress modulator 
GADD153, Caspase 
mediated apoptosis, 
PARP 
(Cheng et 
al. 2010) 
Garcinol HCT-116 15 μM TRAIL mediated 
apoptosis 
(Prasad et 
al., 2010) 
Garcinol  
MDA-MB-231 
and MCF-7 
25 μM Caspase induced 
apoptosis, 
downregulation of 
NFĸβ 
(Ahmad et 
al., 2010) 
 
Garcinol 
 
HT-29, HCT-116 
and IEC-6 cells 
1 μM Inhibition of STAT-1 (Hong et 
al., 2006) 
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Compound (s) Cell line (s) 
Concentration 
used 
Targeted 
Pathway(s) 
Reference 
 
Garcinol 
 
HT 29  
10 μM  
Cell migration, 
Invasion, 
MAPK/ERK & 
PI3K/Akt 
(Liao et al., 
2005) 
 
Guttiferone H and 
Gambogenone 
 
HCT-116, HT-29, 
SW-480 
 
Between 12- 
188µM (for both 
compounds in 
SW480) 
 
Apoptosis and 
antioxidant activity 
(Baggett et 
al. 2005) 
Garcinol A-549, H-460, H-
1299, H-1650, H-
358, and HCC-827 
2 μM Downregulation of  
Aldehyde 
Dehydrogenase 1 
Family Member A1 
(Wang et al. 
2017) 
Guttiferone K HCC 20 μM Cell migration and 
invasion 
(Shen et al. 
2016) 
Garcinol SCC-4, SCC-9 and 
SCC-25 
5, 10 and 15 μM Anti-proliferative, 
pro-apoptotic, cell-
cycle regulatory and 
anti-angiogenic  
(Aggarwal 
and Das 
2016) 
Epigarcinol &       
Isogarcinol 
HL-60 &PC-3 4 and 76 µg/mL  Cell cycle arrest 
(G2/S) and 
antiproliferative 
(Pieme et 
al. 2015) 
Guttiferone K HCT-116 3.4 µmol/L Caspase 3 induced 
apoptosis 
(Li et al. 
2017) 
Garcinol MCF-7 35 μmol/L Down regulation of 
Cyclin D,Bcl-2 and 
Bcl-xl 
(Ye et al. 
2014) 
Garcinol H-1299, H-460 10 μM Decrease of CDK 2,4 
and 6, p38 MAPK 
signaling 
(Yu et al. 
2014) 
Guttiferone K HT-29, CCD-841 
CoN 
5.39 ± 0.22  μM Cell cycle, Cyclin D1, 
D3, CDK 4&6 and 
caspase 3 induced 
apoptosis 
(Kan et al. 
2013) 
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Table 1: A list of in vitro studies that discuss the pathways targeted by benzophenones from 
Garcinia in relation to cancer 
 
One of the well-studied members of the benzophenone family, garcinol (C38H50O6), 
shown in Figure 5 is also listed in the table to give a comprehensive idea of the cancer related 
pathways modulated by this compound. Unlike the compounds used in this study, garcinol is 
freely available to purchase. Some studies have compared the anti-oxidant and anti-cancer 
activity of Garcinol against well know compounds such as curcumin (Padhye et al., 2010). The 
presence of isoprenyl groups is believed to enhance the lipophilicity and hence better cell 
internalization unlike curcumin, whose bioavailability has long been reported to be one of the 
challenges to overcome. A list of in-vivo studies on benzophenones in breast cancer cells, 
including triple negative breast cancer is presented in Chapter 2.  
As a part of our group’s aim to isolate and study bioactive polyphenols from edible fruits, 
we recently reported 5 novel benzophenones from Garcinia paucinervis-,paucinones E-I (1-5), 
and their cytotoxicity across three breast cancer cell lines: MDA-MB-231, SKBR-3 and MCF-7 
cell lines (Li et al., 2016a). Paucinone H turned out to be cytotoxic within the concentration 
ranges of 10 – 20 μM across the panel of cell lines tested. Paucinone G had IC50 values ranging 
Compound (s) Cell line (s) 
Concentration 
used 
Targeted 
Pathway(s) 
Reference 
Guttiferone E  HCT-116, CCRF-
CEM, MDA-MB-
231BCRP 
13.92  μM Activation of Caspases 
3, 7, 8 and 9, 
Alteration of 
Mitochondrial 
Membrane potential 
(Kuete et al. 
2013) 
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from 15 to 23 μM across the panel of cell lines studied. This was followed by paucinone E, 
paucinone F and finally paucinone I with IC50 ranges above 50 μM in MDA-MB-231 and MCF-
7 cell lines. The rationale behind choosing the cell lines mentioned above, was to determine if 
the novel benzophenones displayed cell line specificity. 
Paucinone H (C33H40O7) had strong cytotoxicity (at concentrations ranging from 10 - 20 
μM), across the panel of breast cancer cell lines. Therefore, paucinone H was selected for a 
detailed evaluation of its mechanism of action, particularly in triple negative breast cancer cell 
lines. 
 
Figure 6: Novel benzophenones paucinones E-I isolated from Garcinia paucinervis (Li 
et al. 2016a) 
 
Paucinone E 
Paucinone F 
Paucinone G 
Paucinone H 
Paucinone I 
12 
 
The structural difference between paucinones G and H is that paucinone H lacks the 
hydroxy group attached to C-30 that was present in paucinone G. Other paucinones that have 
been reported from Garcinia paucinervis include: Paucinones, A, B, C and D (Gao et al., 2010). 
In this study, the cytotoxicty of paucinones A, B and D against HeLa cells were attributed to the 
absence of an ester group at C-2 and C-11. 
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Chapter 2: Breast cancer and bioactive compounds from plants 
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2.1. Dietary phytoestrogens and their impact on breast biology  
 
Introduction 
Although phytoestrogens have not been reported in Garcinia, the use of dietary phytoestrogens 
and their impact of breast biology is worth investigating due to the wide spread use of 
phytoestrogen based dietary supplements. Phytoestrogens are plant-derived small molecules that 
can act as potential estrogen receptor agonists or antagonists. Some naturally occurring 
phytoestrogens include coumestans, flavonoids, isoflavonoids, lignans, and stilbenes (Rietjens et 
al., 2017).  Several members of this broad group of plant compounds have been shown to act as 
natural selective estrogen receptor modulators (SERMs), making them attractive agents for the 
prevention of postmenopausal osteoporosis and cardiovascular disease (Moutsatsou 2007; Rudy 
et al., 2012; Poluzzi et al., 2014). Currently prescribed synthetic SERMS such as tamoxifen and 
raloxifene,  are known to cause a number of undesirable side effects such as hot flashes, strokes, 
cataracts, and most notably, tamoxifen  has been reported to increase the risk of uterine and 
endometrial cancers (Hershman et al., 2002). With the need to develop better alternatives to 
currently prescribed SERMs, many investigators and clinicians have assessed the effectiveness 
of several phytoestrogens. However, to date, the clinical benefits of phytoestrogen-based SERMs 
remains to be established.  
The interest in  consumption of dietary phytoestrogens, especially soy mainly stems from 
epidemiological studies that show that the incidence of breast cancer is lower in Asian countries, 
especially China, Japan, Korea, and Indonesia, thus leading to a hypothesis that women whose 
diets are rich in phytoestrogens have a reduced risk of developing breast cancer (Adlercruetz 
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2002). In support of these findings,  the rate of breast cancer incidence increases in Asian women 
who migrate to the west and start consuming a non-traditional diet (Mense et al., 
2008)Therefore, it is clear  that genetic makeup alone is not the reason behind lower incidence of 
breast cancer in Asia. This chapter could serve as a helpful reference for readers who are 
interested in recent advancements in the field of phytoestrogens specifically in relation to breast 
pathophysiology.  
Classification of Phytoestrogens  
The discovery of phytoestrogens was serendipitous through a perplexing case of infertility in 
sheep, and the cause was ultimately determined to be isoflavones from the red clover in the 
pastures (Bennets et al., 1946). Phytoestrogens, are comprised of a structurally diverse group of 
natural products like lignans, flavonoids, isoflavonoids, coumestans, and stilbenes (Ososki and 
Kennelly 2003). While these compounds have been reviewed in depth previously (Ososki and 
Kennelly 2003), the focus of this review is to inform readers on the different classes of 
phytoestrogens, their dietary sources and their estrogenic effects, specifically in relation to breast 
pathophysiology.  
Lignans 
Lignans contain two phenylpropanoid units linked via a carbon–carbon single bond, and two 
well-known lignans are secoisolariciresinol and matairesinol (Ososki and Kennelly 2003). Cereal 
bran, beans, flax seed, nuts, and unrefined grains are some of the important dietary sources of 
lignans. Certain lignans are known to be metabolized to the estrogenic compounds enterolactone 
and enterodiol by the action of gut microbial flora (Cornwell et al., 2004). This gut microbial 
transformation could explain why some women respond to certain phytoestrogens and others do 
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not. Therefore, it can be difficult to establish an effective dose and bioavailability for such 
phytoestrogens in different individuals.  
Isoflavonoids 
Isoflavonoids are a class of flavonoids that have been studied extensively for their estrogenic 
effects. One of the well-studied dietary sources of phytoestrogens is soy (Glycine max) that 
contains two principle isoflavones, daidzein and genistein. In addition, glycetin, formononetin, 
and biochanin A are some of the other well studied dietary phytoestrogens (Preedy 2012). 
Structurally, the presence of a phenolic ring makes isoflavonoids analogous to estradiol, thus 
enabling them to bind to the estrogen receptor (Bedel et al., 2014; Sefirin et al., 2014). Although 
soy is a rich source of isoflavones, other isoflavones have been reported in more than 40 plant 
species (Ososki and Kennelly 2003). Some examples include legumes, such as alfalfa (Medicago 
sativa), chickpeas (Cicer arietinum), common bean (Phaseolus vulgaris), and red clover 
(Trifolium pratense). and Other edible plants such as licorice (Glycyrrhiza glabra) and certain 
whole grains, nuts, and berries also have isoflavones (Rowland et al., 1999). Herbs such as 
Sophora japonica, Pueraria lobata (kudzu), and Radix pueraria (an ingredient used in traditional 
Chinese medicine) are rich in daidzein (El-Halawany et al., 2010; Hong et al., 2011).  
The estrogenic benefits of isoflavones appear to be a function of an intricate balance between the 
bioconversion and bioavailability of isoflavones after they are ingested.  The isoflavone daidzein 
is metabolized into equol by a number of enteric bacteria such as Adlercreutzia, 
Asaccharobacter, Eggerthella,  Lactococcus, and Slackia (Rafii 2015). Equol is one of the most 
bioactive isoflavones, capable of binding to both ERα and ERβ receptors (Kelly et al., 2014; 
Magee et al., 2014). However, the ability to metabolize daidzein to equol varies from one person 
17 
 
to the other, and individuals who are capable of metabolizing daidzein into equol are known as 
equol producers (Shor et al., 2012). Studies have shown that equol is stronger than daidzein in 
inducing the mRNA expression of estrogen-responsive protein PS2 in MCF 7 cells 
(Sathyamoorthy and Wang 1997). The presence of an enteric bacterial population capable of 
metabolizing isoflavones plays an important role in their bioavailability  
Coumestans  
Coumestans are polycyclic aromatic plant secondary metabolites with a carbon-carbon double 
bond shared by a coumarin moiety and a benzofuran moiety. Their estrogenic and anticancer 
effects range from modulating pathways related to cell proliferation, synthesis, and survival 
including ROS production and DNA damage (Nehybova et al., 2014). Coumesterol is an 
important member of this class, and is found in alfalfa, clover sprouts, and pinto beans (Liu et 
al., 2012). Trace amounts of coumesterol have also been reported in spinach and Brussel sprouts 
(Brassica oleracea) (Cornwell et al. 2004) 
Miscellaneous flavonoids 
In addition to isoflavonoids and coumestans, another class of estrogenic constituents are 
prenylflavonoids. One such phytoestrogen is 8-prenylnarigenin, a compound found in hops 
(Humulus lupulus ) (Martina et al., 2008), and has sparked considerable interest in studies 
regarding the potential health benefits of beer consumption. 
 
New phytoestrogens reported for their estrogenic effects in breast cancer  
In vivo and in vitro models are both important in the identification of phytoestrogens and their 
mechanism of action. For example, the erythroidine alkaloids from Erythrina poeppigiana have 
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been reported to be estrogenic, in-vitro using an MCF-7 ER-dependent cell line assay (Lecomte 
et al., 2017b) .This is the first time that an erythroidine alkaloid demonstrated estrogenic activity. 
Transcriptomic analysis of glyceollins (phytoalexins derived enzymatically from daidzein) 
attributed the antiproliferative effects of these compounds to modulation of the FOXM1 pathway 
(Lecomte et al., 2017a). Tanshinone II A, a lipophilic compound isolated from Salvia 
miltiorrhiza (Danshen), has been analyzed for its potential to bind to ER receptors on vascular 
endothelial cells (Fang et al., 2011). Some phytoestrogens elicit cytotoxic/antiproliferative 
effects irrespective of the ER receptor status of a given cell line. For example, arctigenin from 
burdock (Arctium lappa) showed anti-invasive and antimigratory effects on both ER-positive 
(MCF-7) and ER-negative (MDA-MB-231) cell lines (Hsieh et al., 2014). The anti-proliferative 
effects of arctigenin on MDA-MB-231 have also been reported (Hsieh et al. 2014; Maxwell et 
al., 2017). The mechanisms targeted by phytoestrogens on triple negative cell lines is discussed 
in a separate section. 
Edible plants continue to be an important group to study since many women may ingest these 
dietary compounds, either as conventional foods or dietary supplements, without considering or 
understanding their estrogenic potential. Of recent interest is the coffee constituent trigonelline, 
reported to be capable of modifying the rate of cell proliferation in vitro, using estrogen receptor 
positive MCF7 cells (Allred et al., 2009). Diarylheptanoid (DPHD), (3R)-1,7-diphenyl-(4E,6E)-
4,6-heptadien-3-ol, isolated from the rhizomes of Curcuma comosa, showed a protective effect 
against the deterioration of bone microarchitecture in adult female Sprague-Dawley rats 
(Tantikanlayaporn et al., 2013). The phytoestrogen content of foods and dietary supplements 
continues to be an area of active study due to the important health issues surrounding 
phytoestrogens.  
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Phytoestrogens and Estrogen receptors 
Estrogens are steroid hormones that that elicit broad physiological responses and most notably 
play a key role in regulation of the reproductive cycle in women. Estrogens bind to estrogen 
receptors, which regulate transcription of target genes by binding to specific sequences called 
estrogen responsive elements (ERE) (Welboren et al., 2007). There are two specific estrogen 
receptors - ERα and ERβ. The ER ligand binding domains in ERα and ERβ differ by two 
residues: Met-421(ERα)/Ile-373(ERβ) and Leu-384(ERα)/Met-336(ERβ). ERα is primarily 
associated with proliferation, inflammation, and malignancy whereas ERβ is counter active to 
these effects, in the sense that it down regulates the action of ERα regulated genes (Treeck et al., 
2010; Christoforous and Jan-Ake 2011). The binding of certain phytoestrogens to ERβ might 
explain how phytoestrogens could be beneficial (Turner et al., 2007). For instance, genistein, 
apigenin, and daidzein have a greater binding affinity to ERβ (Kuiper et al., 1998). Structural 
similarities of phytoestrogens include the presence of a phenolic hydroxyl group, similar to the 
hydroxyl group in 17β-estradiol. The position of these hydroxyl groups (4,6, and 7 are more 
favorable) and their interaction with the ligand binding domains in ERα and ERβ results in 
activation of the appropriate receptor (Leclercq and Jacquot 2014).  
 
Figure 7: Structure of 17β-Estradiol (E2)(Leclercq and Jacquot 2014) 
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Although phytoestrogens are capable of binding to ER receptors, their relative binding affinities 
to a specific type of estrogen receptor varies. This could in turn explain the differences in activity 
of the same phytoestrogen in different tissue types.  
Dietary sources of phytoestrogens known to impact breast pathophysiology and women’s 
health 
The US food supplement industry has grown significantly from $11 million in sales in 1995 to 
more than $22 billion in 2006 (Bradley 2015). This trend continued further and by 2015, the 
dietary supplement industry was valued at $36.7 billion (Vatistas and Samuels 2012; Bradley 
2015). Flax seed, red clover, soy, and wild yam and are some of the main botanicals containing 
phytoestrogens that are available in the market to treat menopausal symptoms (Borrelli and Ernst 
2010). Single ingredient supplements with chasteberry, cranberry, evening primrose, garlic, 
hops, and don quai have been examined for their potential role in reducing the risk of breast 
cancer in postmenopausal women (Boucher et al., 2013). The use of dietary isoflavones such as 
soy during an individual’s early life has shown to offer protective effects against breast cancer 
(Ziaei and Halaby 2017). Black cohosh, is one of the most popular dietary supplements for 
menopausal women. Although there have been reports that this plant contains the phytoestrogen 
formononetin, some studies have not been able to verify this 
 
The estrogenic activity of black cohosh has been questioned due to the lack of clinical evidence 
(Shulman et al., 2011). However there is no underlying link between consumption of black 
cohosh and an increased risk of breast cancer (Fritz et al., 2014). Similarly, clinical evidence to 
support the use of isoflavonoid-based supplements, like red clover, in the treatment of hot flashes 
and menopausal symptoms have not been significant (Tice et al., 2003). .  
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There is some evidence that shows soy isoflavones like daidzein can enhance cancer 
characteristics in mouse mammary tumor cell lines (Koo et al., 2015; Yang et al., 2015). Other 
studies that have analyzed the use of supplements with multiple phytoestrogens suggest a 
possible interplay between dietary phytoestrogens and increased tumor cell proliferation in vitro, 
thereby advising consumers to avoid them, especially while undergoing breast cancer treatment 
(van Duursen et al., 2013). However, these in vitro models do not completely mimic the 
conditions in humans since in vivo physiological levels and bioavailability are not accounted for. 
To date there is still no strong clinical evidence suggesting phytoestrogens increase breast cancer 
risk, incidence, or progression as reviewed by Moreira (Moreira et al., 2014) 
 
Assays for phytoestrogens 
Detection of phytoestrogens in plant extracts and in dietary supplements is essential for a better 
evaluation of their activity. Therefore, this section discusses assays for the quantification of 
phytoestrogens and the measurement of their estrogenic activity, either as purified compounds or 
as complex mixtures, such as a botanical extract. The limitations of some of these assays are also 
discussed. 
Assays for quantification of phytoestrogens  
 Radio immunoassays have been in use for the detection of daidzein, genistein and formononetin 
since 1972 (Cox et al., 1972). However, quantitative estimation of daidzein in human biological 
fluids such as serum was reported in 1997 (Lapcik et al., 1997). They were found to be an 
efficient alternative to GC-MS or HPLC methods due to their ease, low cost and their ability to 
be used in larger epidemiological studies. Transient gene expression assays, E-screen assays, 
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recombinant yeast assays, laser induced fluorescence detection, UV and IR spectroscopy, 
capillary electrophoresis, MALDI-TOF, ELISA and time-resolved fluoro immunoassays are 
some of the in-vitro systems used to quantitatively measure phytoestrogens (Lapcik et al. 1997; 
Routledge et al., 2000; Garcia-Reyero et al., 2001; Wang et al., 2002). However, each of these 
assays has drawbacks such as the use of radioactive isotopes, being labor intensive, and the 
difficulty in arriving at absolute quantification. Some of these drawbacks can be overcome by 
using quantitative affinity assays based on microchip electrophoresis, that utilize PEG-modified 
glass microchannel with a short run time (often less than 2 minutes) and a small sample volume 
(Chuang et al., 2006) 
 
Bioassays to measure estrogenic activity of phytoestrogens 
The classic ligand binding and ER promoter assays are used to test for estrogenic activity. 
Ligand binding assays, estimate the binding efficiency of a test compound to receptors ERα or 
ERβ, but these assays cannot determine if the compound elicits an estrogenic response (Kuiper et 
al. 1998). Transactivation assays have been used to detect estrogenic activity. For instance, the 
estrogenic activity of dietary lignans has been reported using a  transgenic estrogen reporter 
mouse model (Penttinen-Damdimopoulou et al., 2009). Similarly, Hs578T-ERαLuc and 
Hs578T-ERβLuc cells have been used to identify and characterize ER subtype selective ligands 
(Shanle et al., 2011) 
High-throughput screening assays, based on liquid chromatography mass spectrometry (LC-MS) 
that can provide enhanced sensitivity, selectivity and rapid detailed structural information have 
been developed (Choi and van Breemen 2008) 
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Table 2: Bioassays used in detection and study of phytoestrogens from complex extracts and 
dietary supplements (2008-2017) 
 
Examples of such applications include the use of ER immobilized magnetic particles, to 
eliminate non-specific binding while studying ER-ligand complexes from botanical extracts such 
Assay Principle Significance Reference 
Dual cell line GFP 
expression assay 
Dose response GFP 
intensity in transfected 
MCF7-GFP and Ishikawa-
GFP.  
Rapid identification of 
estrogens, antiestrogens 
and selective estrogen 
receptor modulators. 
Xu et al. 
(2008) 
LC-MS based 
magnetic micro 
particle assay 
ERα and β immobilized 
magnetic particles to screen 
for estrogenic compounds in 
Trifolium pretense (red 
clover) or Humulus lupus 
(hops) extracts. 
Binding of receptors to 
magnetic micro particles 
followed by 
identification of released 
ligands using LC-MS. 
Choi and van 
Breemen 
(2008) 
Micro total bioassay Polydimethylsiloxane sheets 
with micro channels that 
integrate a micro intestine, 
micro liver and target cells. 
Intestinal absorption, 
hepatic metabolism and 
bioactivity of soy 
isoflavones on MCF 7 cells 
was studied. 
Enables study of 
metabolites with shorter 
half-life even at 
negligible volumes.  
Shorter run time and 
lower sample and reagent 
volumes. 
Imura et al. 
(2010) 
Nonspecific 
adsorption assay 
An ERα and β binding assay 
that uses auto fluorescent 
compounds such as 
coumesterol using 
fluorescence polarization. 
The binding of potent 
selective ligands 
determined using 
fluorescence polarization. 
A rapid, simple and 
homogenous method. 
Wang et al. 
(2014) 
HPLC/LC-MS based 
high throughput 
screening assay 
Quantitative estimation of 
isoflavones in dietary 
supplements using tandem 
mass spectrometry. 
A rapid method to 
estimate the composition 
of a single phytoestrogen 
in multiple dietary 
supplement samples. 
 
Andres et al. 
(2015) 
24 
 
as red clover and hops (Choi and van Breemen 2008; Rush et al., 2017). An extension of such 
LC-MS based assays have been reported for chemical and biological standardization of botanical 
extracts with estrogenic compounds (van Elswijk et al., 2004). These methods are particularly 
useful to evaluate phytoestrogen-based supplements, to help ensure that the levels of 
phytoestrogenic compounds in a dietary supplement are standardized and consistent. Such 
standardized extracts would then be a reliable source for clinical studies to assess their safety and 
efficacy, since there is no possibility of variation in results due to a variation in active 
ingredients. LC-MS based assays with an ultrafiltration step are extremely useful in screening 
complex mixtures for ligands and simultaneously estimating their relative binding affinities to 
specific receptors (Sun et al., 2005). In addition, methods such as online biochemical detection 
coupled to mass spectrometry for rapid detection and identification of estrogenic compounds 
from pomegranate peel extract has also been demonstrated (van Elswijk et al. 2004). This 
method is particularly interesting, as it can be used in screening of complex botanical extracts.  
Recently, the use of miniature technology has also been explored to test estrogen-like substances, 
since most of the in vitro assays do not enable simultaneous analysis of bioavailability of an 
estrogenic compound. This drawback has been addressed by the use of  a  micro total bioassay 
made up of polydimethylsiloxane sheets with micro channels that integrate a–micro intestine, 
micro liver and target cells to be tested onto a microchip (Imura et al., 2010). The aim of this 
assay system was to serve as a one-point reference to study intestinal absorption, hepatic 
metabolism and bioactivity of soy isoflavones on MCF 7 cells. The micro intestine channels had 
CaCo2 cells cultured on collagen coated membranes. A fibronectin pre-treated microchannel 
with HepG2 cells formed the micro liver and a suspension of target cells (MCF7) was cultured 
on fibronectin coated micro channels. Unlike conventional bioassays, the micro total bioassay, 
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offers benefits such as a reduction in the volume of reagents and samples used. This unique assay 
system also enables study of sample metabolites with shorter half-life even at negligible 
volumes. Further, the overall assay time was also reduced to two days.  Table 2 shows a list of 
bioassays reported to detect estrogenic compounds while highlighting their unique capabilities in 
comparison to other assays discussed, and their mode of action  
Enhancing the delivery of phytoestrogens   
The low bioavailability of dietary phytoestrogens, suggests that for these compounds to be useful 
physiologically in humans, drug delivery systems may need to be employed to enhance their 
efficacy. A number of factors may impact a compound’s availability, such as the mode of 
administration, presence of certain functional groups, rate of metabolism, activity of binding 
proteins and hydrophobicity play key roles in determining the appropriate drug dosage (Le 
2016). For instance, genistein exhibits poor water solubility, which in turn results in low oral 
bioavailability (Iwasaki et al., 2008; Lee et al., 2009)In order to overcome this issue, a cationic 
lipid-based nano carrier system targeting the mitochondria has been designed for use in cancer 
therapy (Pham et al., 2015). Commercial cationic copolymers such as Eudragit® E have been 
used in a nanoparticle mediated delivery system to improve oral bioavailability of genistein 
(Tang et al., 2011) 
Several in vivo and in vitro studies also explain the role of phytoestrogens in the regulation of 
pro & anti-apoptotic proteins bcl2 and bax. Thus, it can be stated that their ability to modulate 
multiple regulatory pathways is what makes dietary phytoestrogens an attractive panacea. 
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Breast physiology and cancer 
Although considerable advancements have occurred in the last 20 years, in prevention, detection, 
and treatment of breast cancer, it is still one among the most common cancers in woman 
(Anonymous 2016). The incidence rates of breast cancer in the U.S. has decreased since 2000, 
yet it is still higher in comparison to the incidence of breast cancer in Asia. Several 
epidemiological studies hypothesize that the reason for these lower rates of breast cancer among 
Asian women can be attributed to their dietary intake of phytoestrogens (Iwasaki et al. 2008). 
This is further backed up by ethnobotanical information on the benefits of using phytoestrogen 
based herbal preparations and nutraceuticals especially in relation to menopause (Depypere and 
Comhairea 2015). Some studies point out that the reduced risk of breast cancer due to intake of 
phytoestrogens such as soy isoflavones is evident only in Asians and not in western population 
(Dong and Qin 2011). Also, a higher intake of dietary components such as n-3 PUFA, vitamin D, 
phytoestrogen, fiber, and folate, in addition to lower intake of saturated fat, n-6 PUFA, grilled 
meat, and alcohol, has been suggested to be beneficial in reducing the risk of developing breast 
cancer (Kotepui 2016). Molecular targets of phytoestrogens include cell cycle regulatory proteins 
and tumor suppressor genes such as cyclin D1, p53, p21 p27, nerve growth factor and ERα  
(Sakamoto et al., 2010; Chen and Sun 2012; Lecomte et al. 2017b; Lecomte et al., 2017c). Soy 
isoflavonoids, especially genistein has shown antiangiogenic effects, including significant 
reduction in micro vessel density both in vitro and in vivo (Varinska L et al., 2015). Several in 
vivo and in vitro studies also explain the role of phytoestrogens in the regulation of pro- and anti-
apoptotic proteins bcl2 and bax (Rajah et al., 2012). Thus, it can be stated that their ability to 
modulate multiple regulatory pathways is what makes dietary phytoestrogens an attractive 
supplement. 
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Phytoestrogens and triple negative breast cancer 
Breast cancer is a complex interplay of several biochemical, physiological and molecular factors, 
giving rise to different subtypes. One of the most aggressive subtypes is triple negative breast 
cancer (TNBC). This particular subtype is characterized by lack of expression of hormonal 
receptors, estrogen receptor-α (ER-α), progesterone receptor (PR) and human epidermal growth 
factor receptor 2 (HER-2) (Foulkes et al., 2010). Approximately 15% of all breast cancers turn 
out to be triple negative (Lara-Medina et al., 2011).TNBC is known to have higher recurrence 
rates and no approved targeted therapies for these tumor subtypes. There is in-vitro evidence 
suggesting the possibility of utilizing phytoestrogens as effective therapeutics against TNBC. 
These studies range from chemo-protective effects to modulation of key cell survival pathways 
such as cell cycle, cohesion complex cleavage kinetochore formation, NFκβ, and Ras/MAPK/AP 
(Hedelin et al., 2008; Li et al., 2008; Pan et al., 2012; Fang et al., 2016) In addition, gene 
expression profiling studies using microarrays have been reported in various breast cancer 
subtypes including triple negative breast cancer. These studies illustrate the ability of 
phytoestrogens genistein and daidzein have estrogen mimicking activities and alter the 
expression of genes associated with cell communication, lipid metabolism, signal transduction, 
fatty acid synthesis and cell growth (Satih et al., 2010; Guo et al., 2016).  
Further, a recent review reported that the overall risk factor for triple negative breast cancer in 
Asia is the same as in western countries (Wang et al., 2017).  
Although several in vitro studies point to the potential of using phytoestrogens in 
chemoprevention and/or as adjuvants to chemotherapy regimens in aggressive triple negative 
breast cancers, in vivo studies have not shown such promise. In a TNBC xenograft model tumor 
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growth was not affected by oral gavage administration of phytoestrogen-rich soy extract (Gallo 
et al., 2006). The use of phytoestrogens for the prevention or treatment of TNBC requires further 
investigation. Clinical studies are underway to explore the role of phytoestrogens in reducing 
proliferation of triple negative breast cancer (Lathrop 2017). The results of these studies and the 
others to come might hold more clues on the exact application of phytoestrogens across a wide 
demographic. 
 
Phytoestrogens in Hormone replacement therapy 
Hormone replacement therapy (HRT) is the substitution of endogenous estrogens with 
exogenous estrogens, primarily during menopause. Questions about underlying links between 
hormone replacement therapy in women and an increase in incidence of breast cancer, were 
raised after the release of the Women’s Health Initiative study in 1998 (Archer 2014).  As a 
consequence, there was an increasing demand for natural alternatives to HRT (Ross et al., 2000; 
Mueller and Jungbauer 2008). It is at this juncture that phytoestrogens became the focus of the 
research community, due to their structural similarity to human estradiol and their ability to 
modulate the estrogen receptor (Sakamoto et al. 2010).  Hormone replacement therapy for post-
menopausal woman has shown benefits of decreasing risk of fractures, decreasing incidence of 
cardiovascular disease, and delaying onset of Alzheimer’s disease. Studies on the benefits of 
phytoestrogen-rich preparations in perimenopausal women for prevention of atherosclerosis and 
other climacteric symptoms have been only slightly positive (Kirichenko et al., 2017). The 
current knowledge on the clinical benefits of phytoestrogens in hormonal replacement therapy is 
limited (Chen et al., 2015; Franco et al., 2016). The use of phytoestrogens in hormone therapy 
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for menopausal symptoms has also not been successful in breast cancer survivors. (Alipour et al., 
2015). Reviews that have discussed the use of HRT in the treatment of hot flushes in breast 
cancer survivors have also concluded that each patient should be individually assessed for side 
effects of HRT (Wisniewska et al., 2016). Therefore, studies that look at long-term exposure to 
phytoestrogen in a wider demographic might be more invaluable. To this extent, clinical studies 
that include a varied cohort and longer exposure time, such as the Soy Phytoestrogens as 
Replacement Estrogen (SPARE), might help better evaluate the use of phytoestrogens in 
hormone replacement therapy (Levis et al., 2010). Also, given the wide range of phytoestrogen-
based supplements that are promoted for menopausal women, the use of phytoestrogens for these 
symptoms needs to be better investigated 
Phytoestrogens as Selective Estrogen receptor modulators (SERMS) 
SERMS are nonsteroidal compounds that serve as ligands for the estrogen receptor while 
selectively acting as agonists or antagonists. The presence of two different estrogen receptors - 
ERα and ERβ, their tissue specific distribution and binding affinities often determines their 
behavior as an agonist or an antagonist (Jiang et al., 2013). Higher ERαlevels usually correlate 
with an increase in cell proliferation, because ERα is associated with regulation of gene 
expression and proliferation in tissues such as the uterus and breast (Philipp et al., 2013). ERβ on 
the other hand mostly acts as a balance and negates the effects of ERα (Paruthiyil et al., 2009). 
However over 70% of breast cancers are known to express both ERα and ERβ (Charn et al., 
2010) SERMS can act as agonists in tissues such as breast and uterus or antagonists in tissues 
such as cardiovascular cells, bones and brain. This selective specificity of SERMS is the primary 
reason for their therapeutic potential. Major clinical applications of SERM include prevention 
and treatment of breast cancer, osteoporosis and maintenance of healthy serum lipid profile 
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(Martinkovich et al., 2014). Recently, prenylated isoflavonoids have received attention due to 
their ability to act like SERMS. Licorice, hops, and sprouts of leguminous seeds are a rich source 
of prenylated isoflavonoids (Simons et al., 2012)  . Diarylheptanoids from Curcuma comosa 
have been reported for their anti-estrogenic activity by downregulating ERα signaling and 
suppressing estrogen-responsive genes (Thongon et al., 2017) Diadzein and genistein are other 
isoflavones which exhibit SERM like behavior. In other studies, isoflavones such glabidrin, 8-
prenylgenistein, kievitone and phaseollin have shown assay dependent estrogenicity i.e. they 
displayed ER alpha antagonism in a yeast bioassay while they behaved as agonists in human 
breast cancer cell lines (T47D and MCF-7) (Sotoca et al., 2008). A combination of Glabridin and 
Tamoxifen caused inhibition of cell growth in Ishikawa and MCF cell lines. This study points 
out to the potential use of glabridin and tamoxifen in estrogen replacement therapy while 
negating the side effect of Tamoxifen to cause endometrial cancer (Jen et al., 2015). Further 
apigenin, naringenin, quercetin, biochanin A, hesperitin, silymarin and fistein have all reported 
to influence the expression of breast cancer resistance protein (BCRP) (Kaur and Badhan 2015). 
While available data show that phytoestrogens could be used as an alternative to synthetic 
selective estrogen receptor modulators (SERMs), whether the use of phytoestrogens as SERMs is 
entirely beneficial remains a question. For example, there is still a need for studies that focus on 
perinatal exposure to environmental phytoestrogens and their influence on developmental 
epigenetic patterns (Lecomte et al. 2017b).   
Phytoestrogens in breast cancer clinical trials 
Several clinical studies have been conducted with phytoestrogens to further evaluate their 
potential use in humans. A comprehensive list of studies that were completed between 2008 and 
2016, and that focused on breast cancer intervention are listed in Table 2. Since the Women’s 
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Health Initiative study that demonstrated a link between hormone replacement therapy (HRT) 
and breast cancer, there has been an increased interest about whether phytoestrogens would be a 
good substitution for HRT.  In vitro studies suggested that genistein and structurally modified 
isoflavones induced apoptosis and inhibited cell proliferation pathways such as NFKB and AKT, 
suggesting their possible role in chemoprevention and sensitization of tumors to 
chemotherapeutic agents (Sarkar et al., 2006). Data from Mammary carcinoma Risk factor 
Investigation (MARIE), showed genistein causes a decrease in tumor proliferation and Ki-67 at 
high expression levels of Ki-67 (Jaskulski et al., 2017). In contrast no changes were observed in 
Ki-67 in a randomized trials investigating the impact of soy on early stage breast cancer patients, 
however this study also found that transcription of genes associated with proliferation were 
upregulated in woman treated with soy (Shike et al., 2014). Other studies conducted on the use 
of soy and flax seed supplements in healthy females, early stage breast cancer patients and post-
menopausal women have shown upregulation in the expression of genes associated with cell 
proliferation as well (Colli et al., 2012). In a randomized trial investigating healthy woman 
classified as high risk for breast cancer, soy consumption failed to show efficacy in prevention 
and upregulated proliferation markers in pre-menopausal woman within this study (Khan et al., 
2012). Other randomized studies have shown soy to have no effect on modulating breast density, 
a known risk factor for breast cancer (Delmanto et al., 2013; Wu et al., 2015). In healthy post-
menopausal women,  administration of oral doses of soy isoflavones (900 mg/day) proved to be 
safe in post-menopausal women (Pop et al., 2008). The beneficial outcomes of using seaweed as 
a prebiotic catalyst in favorably altering estrogen and phytoestrogen metabolism in a smaller 
ethnic group of 15 women has also been reported (Teas et al., 2009).  
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In addition to the studies reported here, long term projects such as the Korean Hereditary Breast 
Cancer Study (KOHBRA) specifically targeting carriers and non-carriers of BRCA mutations 
might hold some invaluable answers to the long-standing debate on the role of dietary 
phytoestrogens in lowering the risk of breast cancer and the specific populations that would 
benefit from the use of phytoestrogens (Kang et al., 2015). Due to the popularity of 
phytoestrogen-based supplements, the need for more detailed clinical trials has led to an increase 
in number of ongoing studies. A search for ongoing phytoestrogen clinical trials on 
clinicaltrials.gov, showed that results from at least 13 studies are yet to be published.  
 
Phytoe
strogen 
Trial design Results Dose 
Sample 
size 
Age 
(yrs) Reference 
Soy Double blind, 
randomized, 
placebo – 
controlled 
intervention 
Soy intervention 
was neither 
beneficial nor 
induced adverse 
effects on breast 
tissue 
50 mg 
Isoflavone 
tablets per 
day for 12 
months 
102 
(A=44; 
P=41; 
W=17) 
30 – 75   
 
Wu et al. 
[2015] 
Soy  Double blind, 
randomized, 
placebo – 
controlled 
study  
 
Soy isoflavone 
extract did not 
affect breast 
density in post-
menopausal 
women 
250 mg of 
Soy extract 
per day 
80 
(A = 40; 
P=40) 
45  Delmanto et 
al. 
[2013] 
Soy Randomized, 
placebo 
controlled 
study 
Overexpression 
of cell 
proliferation 
genes such as 
FGFR2 
25.8 g Soy; 
Twice/day 
for 30 days 
140 
(A=70; 
P=70) 
50  Shike [2014] 
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Phytoe
strogen 
Trial design Results Dose 
Sample 
size 
Age 
(yrs) Reference 
Soy 
isoflavo
nes 
Double blind, 
randomized, 
Phase 1 
Unconjugated 
isoflavones are 
safe in post-
menopausal 
women, even at 
higher doses 
150 mg 
genistein 
capsules; 
4/day 
30 
(A=18; 
P=12) 
50  Pop et al. 
[2008] 
Soy 
isoflavo
nes 
Randomized 
Phase IIB trial  
Expression of 14 
genes related to 
proliferation, 
apoptosis and 
estrogenic effect 
was observed 
334 mg 
Mixed soy 
isoflavone 
capsules 1 
per day  
98 (A= 
49;P=49) 
25 -55  Khan et al. 
[2012] 
Flax 
seed 
meal 
and 
flax 
seed 
extract 
Randomized, 
placebo 
controlled 
study 
The flax seed 
extract & Flax 
seed meal was 
neither beneficial 
nor did they 
induce adverse 
effects on vaginal 
epithelium or 
endometrium 
1 g FSE & 
90 g 
FSM/day for 
6 months 
90 
(A.FSE= 
30, 
FSM=30; 
P= 30) 
53 - 56  Colli et al. 
[2012] 
Enteroli
gnan 
and 
genistei
n     
Multicentric 
population 
based patient 
cohort study 
using a food 
frequency 
questionnaire 
Inverse 
association 
between genistein 
and Ki-
67expression (in 
post-menopausal 
breast cancer 
patients) 
Lignans – 
per 100 g 
edible food 
Enterolignan 
– per 100 g 
ingested food 
1060 50 -74  Jaskulski et 
al. [2017] 
Isoflav
ones 
(daidzei
n, 
genistei
n & 
glycitei
n) 
Double blind, 
controlled 
study 
Intake of 
isoflavones along 
with exercise 
could be 
beneficial to 
overweight 
postmenopausal 
women 
70 mg 
isoflavone 
capsules for 
6 months 
100 
(A.ISO=
23; 
AEX+IS
O=16; A. 
EX+P=2
5; P=22; 
W=12) 
50 – 70 
yrs 
Choquett et 
al. [2011] 
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Phytoe
strogen 
Trial design Results Dose 
Sample 
size 
Age 
(yrs) Reference 
 
Seawee
d 
supple
mented 
with 
soy 
 
Double blind, 
randomized 
study 
 
Seaweed 
favorably alters 
estrogen & 
phytoestrogen 
metabolism 
 
Seaweed 
capsules (5 
g/d); IS – 
2g/d for 7 
weeks 
 
15 
(SP, GC; 
P) 
 
58 – 70 
yrs 
 
Teas et al. 
[2009] 
 
Flax 
seed 
and 
anastro
zole 
(aromat
ase 
inhibito
r) 
 
2X2 Factorial 
randomized 
intervention 
design 
 
Flax seed did not 
interfere with AI. 
But AI reduced 
the availability of 
circulating 
lignans. 
 
25 g Ground 
Flax 
seed/day for 
13 – 16 days 
 
24 
(AN, 
GFS, 
GFS+P, 
GFS+AN
; P) 
 
59 – 65 
yrs 
 
McCann  
et al. [2014] 
 
Table 3: Clinical studies completed on phytoestrogens and breast cancer intervention (2008-
2017)  
Abbreviations used: A – Active, P- Placebo, W- Withdrawn, FSE- Flax seed extract, FSM – Flax 
seed meal, SP – Seaweed powder, GC – Gelatin capsule, GFS- Ground flax seed, AN-
Anastrozole 
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Figure 8:  A schematic representation of drug delivery systems that utilize phytoestrogens and 
their molecular targets 
One of the key challenges when working with complex botanical extracts is to achieve consistent 
quality control per batch to ensure bioactive compounds do not vary greatly, given that 
environmental factors such as seasonal changes, biotic and abiotic stress, and extraction 
techniques, can have a significant impact on the expression of phytoestrogenic compounds. 
Quality assurance issues with botanical dietary supplements include standardizing the 
concentration and consistency of active constituents and screening for the presence of potential 
impurities and toxic compounds. Recent advances in the biochemical analysis of phytoestrogens, 
such as on-line biochemical detection coupled to mass spectrometry, use of high-throughput 
screening methods such as microchips, micro bioassay systems that mimic the human intestinal 
lumen and biosensors that help detect phytoestrogens in complex plant extracts can  help 
overcome these challenges (van Elswijk et al. 2004; Chuang et al. 2006; Imura et al. 2010). 
However, in the United States, many dietary supplement manufacturers are small companies 
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without the resources to conduct such expensive analyses.  Unless the US Food and Drug 
Administration requires standardization to a bioactive compound, significant levels of variation 
will likely continue to be seen in phytoestrogenic supplements like soy and red clover.  Some 
groups like the United States Pharmacopeia have developed standards for certain herbal dietary 
supplements, but U.S. manufacturers are not required to follow these.  
While there is some evidence in animal studies pointing to the benefits of phytoestrogens, data 
available from studies with human subjects are inconclusive as to whether consumption of 
phytoestrogens is entirely beneficial. This debate holds true even for well-studied phytoestrogens 
such as genistein. For instance, in vitro studies that show incidence of uterine carcinoma, 
multiple oocyte follicle formation, and several studies with conflicting results in human subjects 
on the inhibitory and stimulatory effects of soy on the growth of breast cancer cells emphasizes 
the fact that phytoestrogens should be ingested cautiously with appropriate clinical guidance 
(Duffy et al., 2007; Cederroth and Nef 2009). In addition, the use of dietary phytoestrogens such 
as isoflavones to prevent breast cancer has not shown encouraging results (Sak 2017). Studies 
have even pointed out that genistein interferes with the inhibitory effects of tamoxifen on breast 
cancer cell growth (Liu et al., 2005; Spagnuolo et al., 2015). A meta-analysis of prospective 
studies suggested that high consumption of soy isoflavone decreases risk of breast cancer 
incidence in Asian populations but not in Western populations (Dong and Qin 2011)  
However, a subsequent meta-analysis indicated that soy consumption associates with protective 
effects against breast cancer irrespective of nationality, and may reduce recurrence and mortality 
(Fritz et al., 2013) . The Komen Foundation suggests that breast cancer patients and survivors are 
not required to completely avoid soy. They can include soy based products in their diet, while the 
intake of soy supplements is not recommended. For a comprehensive article highlighting human 
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studies and the relationship between dietary phytoestrogens such as isoflavones and breast cancer 
we also suggest reading the following review (Sak 2017). 
An important question that then remains is whether phytoestrogens would have a protective 
effect at prolonged exposures in lower doses. Studies like this would help determine the long-
term effects of widely marketed phytoestrogen-based dietary supplements and the impact of 
exposure to dietary phytoestrogens. In addition, there is lack of clinical studies on the exposure 
of a fetus to phytoestrogens. So, the risks associated with phytoestrogen consumption in pregnant 
women remains unclear (Todaka et al., 2005). While the general picture is that phytoestrogens 
have beneficial effects and do not induce endometrial or breast cancer, these studies suffer from 
lack of sufficient sample size (Eden 2012). Therefore, additional randomized clinical trials with a 
larger sample cohort would help better understand the effects of these phytoestrogens in a 
pharmacologically relevant dose.  
Since an individual’s ability to metabolize certain phytoestrogens is dependent on the nature of 
the individual’s gut microbial flora, the interplay between an administered dosage and its 
bioavailability can induce significant variability in results. Future studies could therefore utilize 
genetic screening techniques in a personalized medicine approach to understand the genetic 
predisposition of an individual to metabolize phytoestrogens. The completion of the Cancer 
Genome Atlas – a collaborative venture of The National Cancer Institute (NCI) and National 
Human Genome Research Institute (NHGRI) is sure to help better under the molecular 
signatures of various cancer subtypes. This in turn could be helpful in understanding how the 
intake of phytoestrogen supplements would affect breast cancer survivors with specific subtypes 
such as triple negative breast cancer (Tomczak et al., 2015). 
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The use of phytoestrogen-based dietary supplements in the United States has gained great 
popularity in the past two decades since the passage of the Dietary Supplement and Education 
Act (DSHEA) of 1994, although many of their molecular targets and specificity remains under 
investigation. Under DSHEA, botanical supplements, unlike drugs, are not required to 
demonstrate efficacy before being brought onto the marketplace. Some products include health 
claims to describe a relationship between a dietary supplement and a disease, but such claims are 
not required. Manufacturers are required to clearly state in a disclaimer, the weakness in 
scientific evidence (if any), such as mixed research study results or lack of clinical information. 
Disclaimers that state whether or not the FDA approves the claim made by a manufacturer with 
regards to the health benefits of consuming a product/supplement must also to be mentioned in 
the product label (Schneeman 2011). Due to the 1 DSHEA, the FDA’s ability to regulate 
botanical supplements is restricted.  
Therefore, consumers should be aware of these issues when selecting a phytoestrogen-based 
supplement. Whether consumption of phytoestrogen-based supplements is purely beneficial is 
still debatable. So consumers should discuss their individual risk factors such as family history of 
breast cancers with their physicians prior to consumption. Overall, the existing evidence on 
phytoestrogens is encouraging as they appear to be safe when consumed as dietary components 
even in breast cancer survivors. However, there is not enough clinical evidence at this point of 
time to support the use of concentrated or purified phytoestrogens in clinical doses as chemo 
preventive agents. Due to their widespread presence in the human diet, in both conventional 
foods and dietary supplement products, phytoestrogens remain an important area of study, 
especially for women’s health.  
 
39 
 
2.2. Breast cancer pathways modulated by compounds from Garcinia 
Breast cancer continues to be the second leading cause of death in women (Pan et al., 
2015). About 80% of the drugs approved by the FDA for treatment of cancer, within the last 
three decades are directly sourced from plants (Bishayee and Sethi 2016). Natural compounds 
commonly have the ability to modulate multiple oncogenic drivers and pathways which makes 
them ideal for use by themselves or in synergy with existing chemotherapeutic drugs 
(Shanmugam et al., 2011). Some of the well-known drugs obtained from natural sources are: 
Anthracyclines: Doxorubicin, epirubicin and donorubicin. Liposome encapsulated forms of 
doxorubicin help overcome the issue of cardiotoxicity (Karikas 2010). Similarly Paclitaxel 
isolated from the bark of Taxus brevifolia is continued to be used in the treatment of metastatic 
breast cancer, although it was originally approved for treatment of ovarian cancer (Altmann and 
Gertsch 2007). Vinorelbine, a semi synthetic tubulin binding alkaloid that is used in the 
treatment of advanced breast cancer (Jordan and Wilson 2004). Vinca alkaloids are known for 
their ability to stabilize microtubules thus destroying cancer cells. While the recent developments 
in cancer treatment are focused on more patient centric approaches such as immunotherapy, the 
use of natural compounds in cancer management is still an important area of study. Some 
pathways investigated as targets to treat breast cancer are: 
1. Apoptosis 
2. Invasion and Metastasis 
3. Angiogenesis 
5. Cell proliferation 
6. Self-sufficiency in growth signals 
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Compounds from Garcinia that have been studied and reported under each of the above-
mentioned pathways in breast cancer cell lines are discussed here: 
Apoptosis 
Apoptosis or “programmed cell death” involves execution of damaged or unwanted cells by the 
human body, primarily with the use of enzymes known as caspases (Kritsanawong et al., 2016). 
The two major pathways of apoptosis are: Intrinsic pathway and Extrinsic pathway. The extrinsic 
pathway involves activation of initiator caspases-8 mediated through the activation of ligands 
such as tumor necrosis factor-α (TNF-α), TNF-related apoptosis inducing ligand (TRAIL) and 
cluster of differentiation 95 ligand (CD95L/Fas ligand (FasL)(Mellier et al., 2010). The intrinsic 
pathway on the other hand begins with DNA damage and depolarization of mitochondrial 
membrane, involving Bcl2 proteins, cytochrome C and finally the activation of caspases 3 or 9 
(Kim 2005). 
Camptothecin, etoposide, paclitaxel and vinblastine are some of the plant derived 
chemotherapeutic drugs whose mechanism of action is apoptosis (Feng et al., 2014).  Plant 
derived polyphenols have been known to induce endoplasmic reticulum related stress 
contributing to apoptosis. Being a rich source of polyphenols, several members of Garcinia 
species have been shown to induce activation of caspases thus initiating the mechanism of 
apoptosis (Acuña UM et al., 2009). α mangostin, a xanthone that occurs in a few Garcinia 
species like Garcinia mangostana has been reported to induce apoptosis by the activation of 
caspases 3 and 9 by modulating HER2/PI3K,Akt and ERK1/2 (Kritsanawong et al. 2016). 
Gambogic acid and guttiferone K are other compounds in Garcinia species that are known to 
induce apoptosis by activation of caspases 3,8 and 9 (Shi et al., 2013);(Kan et al. 2013). In 
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addition, oblongifolins F, G and xanthones from Garcinia oblongifolia have been reported to 
initiate apoptosis by activation of caspase 3 (Feng et al. 2014). Triterpenoids from Garcinia 
celebica have also reported to induce apoptosis by increasing the expression of PARP and 
inhibiting Akt (Subarnas et al., 2016). Cambogin, gambogenic acid, neogambogic acid and 
gambogic acid are other polyphenols from Garcinia have also shown to induce apoptosis by 
inhibition of STAT-3 phosphorylation, increased expression of caspases 3, 8 and 9 and increased 
expression of Bax/Bcl2 (Prasad et al., 2011; Wang et al., 2011; Zhou et al., 2013). Literature 
points out to the apoptosis inducing potential of Garcinia polyphenols including benzophenones 
(Protiva et al. 2008).Therefore, the possibility of caspase mediated apoptosis in TNBC cells by 
the novel benzophenones was considered to be important. The approach and results are discussed 
in detail in Chapter 3.  
 
Invasion and metastasis 
About 50% of women diagnosed with breast cancer are likely to develop metastasis (Chun and 
Kim 2013). The leading cause of deaths due to cancer are in fact due to metastasis and not from 
the primary tumor itself (Melzer et al., 2017).The term metastasis refers to the process by which 
tumor cells detach from the primary site, migrate to one or more distant sites an form secondary 
tumors (Tsai and Yang 2013). Metastasis involves the following series of events: i) Detachment 
of cells from the primary tumor involving epithelial mesenchymal transition (EMT) ii) Migration 
of tumor cells into the blood or lymphatic system mediated by matrix metalloproteinases and iii) 
Interaction of tumor cells with target organs such as lungs, liver and bones (Chun and Kim 
2013). Often patients who present metastatic disease are incurable. Therefore, there is a need for 
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dietary agents which by themselves or in synergy with chemotherapeutics are capable of 
suppressing metastasis (Doi et al., 2009). Garcinol in synergy with Taxol has shown to inhibit 
metastasis by modulating epithelial mesenchymal transition (EMT) in mouse mammary 
carcinoma 4T1 cells (Tu et al., 2017). In another study α mangostin inhibited metastasis of 12-O-
tetradecanoylphorbol-13-acetate (TPA) induced matrix metalloproteinase-2 and 9 in MCF7 cells 
(Lee et al., 2010). In addition, administration of Panaxanthone (which is a combination of 78% α 
mangostin and 16%γ mangostin) inhibited metastasis in a mouse mammary cancer model via 
inhibition of proliferating cell nuclear antigen (PCNA) (Doi et al. 2009). Similarly, garcinol 
reversed epithelial-to-mesenchymal transition in MDAM-MB-231 and BT-549 cells. The 
mechanism of action was found to be through upregulation of E cadherin and down regulation of 
markers vimentin, ZEB-1 and ZEB-2 (Ahmad et al. 2012b). As evident from the above-
mentioned studies, garcinol is the only Garcinia derived polyphenol that has been explored for 
its antimigratory effects in breast cancer cells. The scarce literature available about this aspect of 
Garcinia benzophenones, makes it worth investigating 
Angiogenesis 
Angiogenesis is the formation of new blood vessels from preexisting micro vessels (Pandya et 
al., 2006). Studies on the anti-angiogenic activity of compounds from Garcinia on breast cancer 
cells are limited. Although the total number of studies reported on the anti-angiogenic activity of 
Garcinia compounds is 25. In addition to these studies, use of Garcinia compounds in anti-
psoriatic treatments and other carcinomas have been reported (Li et al. 2013). But only two 
studies reported the use of purified Garcinia compounds on breast cancer cell lines. In one of 
these studies, garcinol in combination with Taxol  induced cell cycle arrest (G2/M) and caused 
inhibition of caspase-3/cytosolic Ca2+-independent phospholipase A2 (iPLA2) and nuclear 
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factor-κB (NF-κB)/Twist-related protein 1 (Twist1) which in turn inhibited angiogenesis in a 
mouse 4T1 breast model (Tu et al. 2017). In another study, α mangostin caused a significant 
decrease in Akt phosphorylation in mammary tumors carrying a p53 mutation. Consequently, α 
mangostin inhibited angiogenesis among other key cell survival pathways (Shibata et al., 2011) 
Anti-proliferative action  
Gambogic acid is a known inhibitor of signal transducer and activator of transcription 3 (STAT-
3) signaling, in addition to its targets such as vimentin, keratin 18 and calumenin in MDA-MB-
231 cells, thereby causing a decrease in cell proliferation in a dose dependent manner (Sulaiman 
et al., 2016);(Li et al., 2015). Phosphorylated STAT-3 (p - STAT3) – the active form of STAT-3 
is often elevated in cancers, thus promoting cell proliferation and tumorigenesis by promoting 
resistance to apoptosis (Page et al., 2011). In addition, the expression of STAT-3 is transient in 
normal tissues (Furtek et al., 2016). Therefore, STAT-3 inhibitors could be used to selectively 
target tumor cells. Garcinol is the only benzophenone from Garcinia that has been reported to 
inhibit STAT-3 (Ahmad et al. 2012a). Therefore, study of small molecule STAT-3 inhibitors 
from Garcinia could be helpful. 
Mitogen activated protein kinase (MAPK) signaling pathway is involved in cell proliferation, 
differentiation and motility and is often mutated in human cancers (Rauch et al., 2016). This 
makes them one of the well-studied targets for the development of anti-cancer drugs (Caunt et 
al., 2015). Inhibition of cell proliferation via modulation of HER2/MAPK signaling by α 
mangostin has also been reported in T47D (Human Breast Carcinoma) cells (Kritsanawong et al. 
2016). Panaxanthone, a xanthone from the pericarp of Garcinia mangostana reported for the first 
time, showed significant anti-proliferative activity on a mouse metastatic mammary cancer 
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model via inhibition of proliferating cell nuclear antigen PCNA (Doi et al. 2009). Fruit extracts 
of Garcinia mangostana also induced antiproliferative effects on SKBR-3 cells (Moongkarndi et 
al., 2004). Friedolanostane triterpenoid from the leaves from Garcinia subeliptica has been 
reported for its dose dependent antiproliferative effects on MCF-7 cells (Subarnas et al. 2016). 
Two prenylated xanthones from the branch extracts of Garcinia achachairu have also been 
reported for their anti-proliferative and cytotoxic effects on MCF-7 cells (Mariano et al., 2016). 
While these studies focus on anti-proliferative effects of compounds derived from Garcinia on 
several breast cancer cells, none of them specifically studied anti-proliferative pathways and 
associated markers only in triple negative cell lines. Other studies in which anti-proliferative 
effects were attributed to cell cycle arrest and apoptosis are discussed in the appropriate sections.  
Modulation of protein transport and cell cycle arrest 
Cyclin dependent kinase (CDK) 4/6 inhibitors have most recently gained attention as selective 
drugs to induce G1 phase cell cycle arrest and cause inhibition of tumor progression (de Groot et 
al., 2017). Interestingly, several compounds isolated from Garcinia have shown to be successful 
inhibitors of cell cycle proteins such as the cyclins. These studies are discussed in this section. 
Gambogic acid which is currently in clinical trials in China has been identified as an inhibitor of 
nucleocytoplasmic transport of proteins by regulating nucelophosphin and Nup88. This results in 
apoptosis and cell cycle arrest in HL60, Jurkat cells an U937 cells (Shu et al., 2008). Increased 
G1 phase and a reduction in S phase population was observed in mouse mammary carcinoma 
 BJMC3879luc2 cells treated with α mangostin (Shibata et al. 2011). The xanthone isobractin 
from Garcinia bractea has been shown to induce G0/G1 phase cell cycle arrest via reduced 
expression of cyclins D1 and E (Shen et al., 2014). One of the well-known xanthones α 
mangostin was shown to cause G1 phase arrest and a reduction in the S phase in MDA-MB-231 
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cells. Increased expression of p21cip1 and CHEK2 lead to reduced expression of CDKs and 
cyclins (Kurose et al., 2012). Inhibition of G0/G1 phase of the cell cycle in MCF7 cells has also 
been reported on treatment with neogambogic acid (Wang et al. 2011). A G1 phase arrest and S 
phase suppression of the cell cycle were observed in a mouse mammary metastatic cancer model 
upon treatment with α mangostin (Shibata et al. 2011). Panaxanthone isolated form the pericarp 
of Garcinia mangostana caused arrest of G1 phase accompanied by significant decreases in cell 
population in the S and G2 phase (Doi et al. 2009). Stabilization of microtubules is an 
established mechanism of action of Taxol, which is currently used in the treatment of cancer. 
Gambogic acid, induced cell cycle arrest in the G2/M phase in MCF-7 cells by stabilization of 
microtubules (Chen et al., 2008). As evident from the studies listed above, most of the Garcinia 
benzophenones and even xanthones have been able to cause a G1 phase arrest and a decrease in 
M phase of the cell cycle. Often the G1 phase accumulation is influenced by the inhibition of 
cyclins. The catechol and enol functional groups and the presence of prenyl groups have been 
associated with the activity on tubulin and microtubules which could explain the decrease in M 
phase of the cell cycle (Wu et al. 2014). Given the lack of the three common receptors ER, PR 
and HER2 in TNBC, the use of a compound that selectively targets cell cycle progression in 
tumor cells could be of interest. 
As mentioned above, there are multiple pathways related to cancer, that compounds from 
Garcinia can modulate. Since the scope of this study was limited to TNBC, pathways that are 
relevant to the etiology and progression of TNBC were chosen for detailed analysis.  
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2.3 Triple negative breast cancer – Introduction 
TNBC (Triple negative breast cancer) is characterized by the lack of 3 cell surface 
receptors: Estrogen receptor (ER), Progesterone receptor (PgR) and Human epidermal growth 
factor receptor (HER2). About 15 to 20% of all diagnosed breast cancers are triple negative and 
are prevalent in younger women, especially of African American or Hispanic origi n (Carey et 
al., 2010). The lack of expression of the 3 common receptors (ER, PgR and HER2) which are 
also the known molecular targets, leaves the only treatment option for TNBC to be conventional 
chemotherapy (Bianchini et al., 2016). Although patients with a mutation in BRAC1 often are 
diagnosed as triple negative, all triple negative breast cancers are not BRCA1 positive (Bulfoni 
et al., 2016; Massihnia et al., 2016). Recent studies such as the Cancer Genome Atlas, have 
revealed more information that has led to subcategorization within the broad umbrella of triple 
negative breast cancer (Herold and Anders 2013). Basal like subtypes BL1 and BL2, 
Immunomodulatory subtype, mesenchymal subtype, luminal androgen receptor subtype are the 
categories reported, based on gene expression profiling (Prat and Perou 2011). The 
heterogenicity of these cancers makes chemotherapy the only treatment option. Therefore 
development of more targeted approaches to treat TNBC is a topic that the research community 
is focused on at the moment. 
Molecular profiling studies have revealed that the common genetic alterations found in 
TNBC are loss of tumor protein TP53, activation of PI3K pathways, alterations in DNA damage 
repair genes and loss of RB1 and BRCA1 (Oualla et al., 2017). Now that these pathways are 
known and studied in TNBC, targeting these pathways could help in stopping the progression of 
TNBC. To this extent, platinum salts and poly ADP-ribose polymerase (PARP) inhibitors, use of 
monoclonal antibodies to inhibit growth factors such as EGFR, VEGFR and FGFR are currently 
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being explored for use in treatment against TNBC (Corkery et al., 2009). Other molecular targets 
that are being explored for the development of targeted therapeutics are JAK2/STAT3 pathway, 
inhibition of notch signaling and blockage of Androgen Receptor (AR) (Cancer Genome Atlas 
2012). 
Several natural compounds have been explored for their role in treatment of TNBC by 
themselves or in an adjuvant setting. Experimental results reported within the last seven years, 
that discuss the specific pathways modulated by natural compounds against triple negative breast 
cancer are discussed below.  
A sesquiterpene lactone analog DETD-35 obtained from Elephantopus scaber L, a 
member of traditional Chinese medicine induced significant oxidative stress followed by ER 
stress mediated apoptosis or paraptosis like cell death in an MDAMB-231 xenograft mouse 
model (Shiau et al., 2017). This study is particularly interesting as DETD-35 proved to be a 
promising agent for the treatment of apoptosis resistant cancer and TNBC. In another study, 
manuka honey showed specific antitumor effects against MDA-MB231 and MCF-7 while 
sparing normal breast epithelial cells MCF-10A (Aryappalli et al., 2017). The mechanism of 
action was via activation of caspases 8,9,6,3 and 7. A significant reduction in tyrosine 
phosphorylated STAT-3 was also observed in both the cell lines studied. This further coincided 
with a decrease in production of interleukin-6 (IL-6). STAT-3 pathway has been known for its 
role in oncogenesis of breast cancer. Also, MDA-MB-231 cells express constitutively activated 
STAT-3 (Banerjee and Resat 2016). The cancer specific activities of manuka honey in this study 
were attributed to its flavonoids and phenolic constituents. Several molecules have been screened 
for cytotoxic effects in vitro on TNBC cells (Bao et al., 2017; Dziwornu et al., 2017). An 
indolin-2-core novel molecule was reported to be a potent inhibitor of TNBC cells (Zhou et al., 
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2017). Curcumin the polyphenol that has been well studied for its ability to modulate multiple 
signaling pathways has also been explored for its therapeutic potential against TNBC. To this 
extent two analogs of curcumin have been reported for the first time in selectively inducing ROS 
mediated apoptosis in a TNBC xenograft model on intraperitoneal administration (Pignanelli et 
al., 2017).  
Some studies also report the use of plant extract and one or more pure compounds for 
their activity against TNBC. Leaf extracts of Cynara cardunculus and its active ingredient 
cynaropicrin caused upregulation of p21Waf1/Cip1 , G2 phase cell cycle arrest via modulation of 
cyclin B and CDK1 as well as downregulation of phospho(Ser 473)-Akt in MDA-MB-231 
(Ramos et al., 2016). Ethanol extract of propolis and caffeic acid phenethyl ester exhibited 
significant cytotoxicity on MDA-MB-231 and Hs578T cells (Rzepecka-Stojko et al., 2015) . 
Piperine an alkaloid isolated from Piper nigrum and Piper longum has shown TRAIL induced 
cytotoxicity in TRAIL sensitive and resistant TNBC (Abdelhamed et al., 2014). Microtubule 
targeting agents like the current chemotherapeutic drugs such as paclitaxel, vinblastine and 
vincristine are also being explored for their use as TNBC therapeutics. In a recent study, 
acridones were studied on MDAM-MB-231 cells and identified as being able to cause cell cycle 
arrest in G2/M phase in addition to inducing apoptosis and disruption of microtubules by binding 
to the colchicine binding site of tubulin (Magalhaes et al., 2016). Basal like TNBCs have been 
known for their sensitivity to DNA damaging agents relative to other TNBC subtypes (Lehmann 
et al., 2011). Maximiscin displayed selective cytotoxicity against MDA-MB-468 in comparison 
with other TNBC cell types. In addition to being cytotoxic, maximiscin caused an accumulation 
of G1 phase in cell cycle followed by phosphorylation of checkpoint kinases 1 and 2 (CHK1 and 
2) which are involved in DNA damage check points. In addition to its in-vitro effects, 
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maximiscin also inhibited growth of MDA-MB-468 xenografts. Defective DNA repair systems 
in addition to higher basal levels of DNA and high proliferation rates were discussed as causes of 
increased BL1 sensitivity to DNA damaging agents (Robles et al., 2016). Similarly, a compound 
reported for the first time - Zj6413 in synergy with chemotherapeutics showed synergistic 
antitumor effects in vitro and in vivo on MDA-MB-453 cells via inhibition of Poly(ADP-ribose) 
polymerases (Zhou et al., 2016). In addition to mechanisms that target DNA damage, 
compounds derived from plants have also been studied for their anti-migratory effects against 
TNBC. A piper amide like compound (NED-135) caused significant inhibition of matrix 
metalloproteinase (MMP)-9 in MDA-MB-231cells  (Kim et al., 2015). In addition, NED-135 
also inhibited activation of signaling molecules Akt, ERKs and p38 MAPK in sphingosine-1-
phosphate (SP1) induced MCF10A cells (Kim et al., 2011). Similarly, diallyl trisulfide (DATS) 
isolated from garlic inhibited the protein and enzyme activities of MMP2/9 via downregulation 
of NFĸB and MAPK pathways in MDA-MB-231 cells (Liu et al., 2015). In another study, a 
compound 3,4 methyenedioxy-β-nitrostyrene, exhibited strong anti-metastatic effect on TNBC 
cells without affecting cell viability. The underlying mechanism was reported to be inhibition of 
Focal adhesion kinase (FAK) phosphorylation as a result of reducing β1 integrin activation 
(Chen et al., 2015a). 
The number of studies that report compounds isolated form Garcinia for their activity on 
TNBC cells are limited. These studies have already been discussed in Chapter 2.1. The closest 
structural relative of the benzophenones that are discussed in this research is garcinol. Although 
the studies on garcinol’s anti-cancer effects on TNBC cells are listed in Chapter 1, important 
studies that served as a guide for my research will be discussed in this section. Garcinol is known 
to induce apoptosis visa down regulation of NF-ĸB. In addition, it has also been reported to 
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reverse epithelial-mesenchymal transition in MDA-MB-231 and BT-549 breast cancer cells 
(Ahmad et al. 2012b; Tu et al. 2017).  
Triple negative breast cancer cell lines used in my research were: MDA-MB-231 and 
MDA-MB-468. MDA-MB-231 is classified as basal type 2 with mesenchymal features and 
vimentin expression. Whereas MDA-MB-468 is epithelial basal type 1 with keratin 5 expression. 
Further, 231 has a wild type PI3K pathway and 468 has a PTEN homo deletion and amplified 
EGFR (Chavez et al., 2010). Other characteristics of the basal subtype are : loss of TP53,RB1, 
BRCA 1, MYC amplification and activation of phosphatidyl inositol 3 kinase (PI3K) (Herold 
and Anders 2013). Although the availability of limited quantities of the novel compound 
paucinone H only enabled studying its effects on MDA-MB-231 cells, results of a cell viability 
study showed that the IC50 ranges of paucinone H on both MDA-MB-468 and MDA-MB-231 
varied from 19 to 25 µM. The study and its results are discussed in detail in Chapter 3. 
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Chapter 3: Molecular mechanisms targeted by benzophenones from Garcinia paucinervis 
against breast cancer cell lines with varying receptor status 
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Five novel compounds: paucinone E (1), paucinone F (2), paucinone G (3), paucinone H (4), and 
paucinone I (5) were tested on a panel of breast cancer cell lines: MDA-MB-231, MCF-7 and 
SKBR-3. Among the compounds that were screened, paucinone H exhibited significant anti-
proliferative, apoptotic and anti-migratory effects against MDA-MB-231. IC50 values of 
paucinone H ranged from 10 to 19 µM across the panel of cell lines. At half the IC50 
concentration (10 µM), paucinone H induced significant anti-migratory effects and a reduction in 
mitosis. Further analysis of paucinone H could help understand the potential application of 
paucinone H by itself or in synergy with other therapeutic agents against TNBC. 
Garcinia species have been used in traditional Chinese and Ayurvedic preparations for their 
wide range of biological activities (Hemshekhar et al. 2011; Kumar et al. 2013). Compounds 
from Garcinia have been studied for their ability to modulate multiple signaling pathways 
ranging from caspase dependent/independent apoptosis to MEK pathway (Protiva et al. 2008; 
Einbond et al. 2013). Especially, the cytotoxicity of selected xanthones from Garcinia spp. have 
been reported in breast cancer cell lines (Kritsanawong et al. 2016; Mariano et al. 2016; Sun et 
al., 2016; Mohamed et al., 2017; Youn et al., 2017). However, another class of polyphenols 
known as benzophenones that have a unique structure and diversity have been least explored, 
particularly in triple negative breast cancer cells (Wu et al. 2014). Only a total of two studies 
have explored the use of benzophenone garcinol against triple negative breast cancer. One of 
them analyzed the synergistic effects of existing chemotherapeutic agent Taxol (Tu et al. 2017). 
This study revealed that low doses of Taxol in combination, with garcinol in a metastatic mouse 
mammary carcinoma model could downregulate key cell survival events such as cell cycle, 
angiogenesis and metastasis. In another study, garcinol was found to reverse epithelial-
mesenchymal transition in MDA-MB-231 cells (Ahmad et al. 2012b). The possible mechanism 
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of action was suggested to be upregulation of E-cadherin and downregulation of vimentin, ZEB-
1 and ZEB-2. Recently we reported the identification of five novel benzophenones from 
Garcinia paucinervis and their cytotoxicity against a panel of 3 breast cancer cell lines with 
varying receptor statuses: MDA-MB-231 ER-,PR-,HER2-; SKBR-3 HER2+ and MCF-7 ER+ 
(Li et al. 2016a). During our initial studies, we identified that one of these benzophenones was 
active against MDAM-MB-231. This was the rationale behind our interest to delve deeper into 
the mechanism of action of these compounds  
3.1 Materials and Methods 
Plant material and extraction 
Garcinia paucinervis seeds were collected from Xishuangbanna, Yunnan Province, in People’s 
Republic of China, the specimens were identified by one of the authors Dr. Chun lin Long. The 
voucher specimens (YN20144538) were deposited in the Herbarium of Minzu University of 
China in Beijing, People’s Republic of China. Air dried Garcinia paucinervis seeds were the 
starting material for the extraction process. Powdered seeds were extracted twice with 2L of 95% 
ethanol and allowed to soak for two days. This solution was then filtered and concentrated under 
a reduced pressure of 40◦C from which 320 g of crude extract was obtained. The extract was then 
dissolved in 800 ml of water. After a solvent-solvent portioning with petroleum ether, 140g of 
the upper phase was removed. The residue (120 g) was then purified by silica gel column 
chromatography (120x10 cm) and eluted with a solvent system of petroleum ether and acetone 
(100:0 to 0:100 and 800 ml of each fraction was collected and concentrated, to yield 9 combined 
fractions as follows: Fr. A-Fr. I,0.5,2.2,2.1,1.5,2.0,7.8,13.2,5.1, and 6.0 g respectively). Each 
fraction was later analyzed by UPLC-QTOFMS before commencing preparative-scale isolation. 
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Isolation of Paucinone H from Garcinia paucinervis seed fraction  
 Additional amounts of paucinone H was isolated based on need for use in bioassays. Since 
collection of Garcinia paucinervis fruits was not feasible, a previously isolated fraction of 
Garcinia paucinervis seed was used to isolate additional amounts of paucinone H needed for 
bioassay studies. The scheme of isolation is shown in Figure 9. 
      
Figure 9: Isolation of paucinone H from Garcinia paucinervis seed Fraction D 
Yield: 332.5 mg Fraction = 0.3 mg paucinone H 
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Briefly, 332.5 mg of fraction D was fractionated over Sephadex LH-20. A total of 40 
fractions were obtained and scanned for paucinone H as reported (Li et al. 2016a). Fractions 15, 
20, 24, 29 and 35 were scanned for paucinone H using a UPLC-QTOF Acquity UPLC system 
(Waters Corporation, Milford, MA, USA) coupled with QTOF-MS (Xevo G2 QTOF, Waters MS 
Technologies, Manchester, UK). The fractions are shown in Figure 10. Out of the scanned 
fractions 24, 29 and 35 showed presence of paucinone H as marked in Figure 10. These selected 
fractions were then recombined and dried down to be weighed and used in preparative scale 
isolation of paucinone H. The purity of paucinone H isolated by this method was estimated to be 
≤ 98%. The isolated compound was then sealed in a vial and stored at -4◦C until use in bio 
assays. The UPLC -QTOFMS profile of the isolated compound is shown in Figure 11. 
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Figure 10: UPLC-QTOFMS profile of Garcinia paucinervis seed fractions obtained from 
Fraction D.  
The forty fractions obtained by Sephadex separation were scanned for paucinone H. Shown in 
the figure above are fractions 24, 29 and 35 with their total ion content and the chromatograms 
extracted for paucinone H. Fractions 15 and 20 did not have paucinone H 
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Figure 11: UPLC-QTOFMS profile of seed fractions showing paucinone H. a, b and c denote 
fractions 35, 24 and 29 respectively. Paucinone H is marked with an arrow. 
 
 
 
 
 
 
Figure 12: UPLC-QTOFMS profile of paucinone H after isolation. 
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A stock solution of 2 mM concentration was prepared with DMSO, for use in bioassays. 
This stock solution would then be diluted to the appropriate concentration required for each 
experiment. Care was taken to ensure that the concentration of DMSO never exceed 0.01% in the 
treatment wells. This stock solution was sealed in a vial and stored at -4◦C. The time frame 
between isolation of the compound and use in bioassays was approximately 4 months. 
Cell culture 
MDA-MB-231 and MCF-7 cells were purchased from American Type Culture Collection 
(Rockville, MD) and cultured in DMEM glucose medium (Gilbco, USA) supplemented with 
10% fetal calf serum and 100 µL of antibiotics (penicillin and streptomycin). SKBR-3 cells were 
cultured in DMEM F12 glutamine medium supplemented with 10% fetal calf serum and 100 µL 
of antibiotics (penicillin and streptomycin). All cell lines were maintained in an incubator at 37 
°C with 5% CO2. 
Growth inhibitory effects on a panel of breast cancer cells 
All compounds tested in vitro were dissolved in DMSO and diluted with required volumes of 
respective cell culture media before each treatment. To determine the cytotoxic effects of test 
compounds on the three cell lines used in this study, exponentially growing cells (12 × 103 
cells/well) were seeded in 96 well multitier plates. After 24 h, each test compound was added to 
each cell line used in his study. Concentrations of the compounds studied ranged from 5 to 200 
µM. Doxorubicin was used as a positive control. After 48 hours of treatment, a cell viability 
assay (WST) was performed. Each well was washed twice with serum-free medium followed by 
the addition of a 150 µL of 10% WST solution. The plates were wrapped in aluminum foil and 
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incubated for 1 h, their absorbance was then read at 440 nm using a Spectra Max plate reader. 
Each experiment was performed in triplicate. Average absorbance and the percentage inhibition 
relative to control was calculated. Results were analyzed using Graph Pad Prism (v 6.01) (Graph 
Pad Software, San Diego, CA, USA), and IC50 values were estimated. 
Apoptosis assay to identify increase in apoptotic cells after treatment with paucinone H 
Propium Iodide was used to identify apoptotic cells. MDA-MB-231 cells were plated at a density 
of 12 × 103 cells/well in a 96 well plate. Each well was subjected to treatment with Control, 
paucinone H 5 and 20 µM respectively 24 hours after plating.  After a treatment time of 48 
hours, 5 µL of PI buffer was added to the wells.  Each well was then imaged three times to 
capture fluorescence. Average fluorescence relative to control was then used to calculate 
percentage of apoptotic cells. 
Immunostaining for mitotic marker phospho-histone 3  
MDA-MB-231 cells were seeded at a density of 12 × 103 cells/well in chamber slides and 
allowed to form a monolayer. After seeding, paucinone H was added to the wells at a 
concentration of 10 µM. 24 hours after treatment, cell culture medium was removed, and cells 
were fixed with 4% Paraformaldehyde (PFA) followed by incubation with a blocking buffer 
comprising of 2% BSA in PBS. The primary antibody Phosphohistone (SER 28) (Cell signaling; 
1:200) was then added to the set up and allowed to incubate overnight in a wet chamber at 4 °C. 
DAPI was used to counterstain DNA. The secondary antibody used in this procedure was Alexa 
Fluor® 488 anti-rabbit IgG (Cell signaling; 1:1000). Images were captured using a Zeiss live cell 
fluorescent imaging system. Each treatment well was imaged 3 times and percentage mitotic 
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cells were calculated relative to control. Statistical analysis was done using Graph Pad Prism (v 
6.01) (Graph Pad Software, San Diego, CA, USA)  
Wound healing assay 
MDA-MB-231 cells were allowed to form a confluent monolayer 24 hour prior to start of the 
experiment. A 20-200 µL pipette tip was then used to create a scratch ˜ 1mm in width. The wells 
were gently washed twice with PBS and replenished with specific concentrations of paucinone H 
in FCS free media. Wound closure was monitored over 48 hours and images were captured using 
a live cell imager (Magnification=10X). Wound closure relative to control was then calculated 
using the measure and analyze tools in Graph Pad Prism (v 6.01). Results were verified in two 
individual experiments with duplicates. 
Statistical analysis 
All data presented here are from at least 2 independent experiments done in triplicate. Statistical 
analysis was performed using Graph Pad Prism (v 6.01). Statistically significant differences 
between the control and treatment groups were calculated by Student’s t test except for the 
increase in apoptotic cells in which case ANOVA was used. P values < 0.05 were statistically 
significant. 
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3.2 Results 
Growth inhibitory effects of paucinones on a panel of breast cancer cell lines with varying 
receptor statuses 
The five isolated compounds (1-5) were evaluated for cytotoxicity against a panel of human 
breast cancer cells including MDA-MB-231, SKBR-3 and MCF-7 using a WST assay (Table 1). 
Cell lines for this study were chosen based on their varying receptor status i.e. MDA-MB-231 
are ER-, PR-, HER2- and SKBR-3 is HER2+ while MCF-7 is ER+. Cells were treated with test 
compounds for 48 hours. Compounds (2), (3) and (4), had IC50 values <50 µM on the panel of 
cell lines used. Interestingly, paucinone H (4), was the most active among the panel of 
compounds tested (IC50 values ranging from 10 to 19 µM). Doxorubicin was used as a positive 
control (IC50 < 3µM) in our experiments. Compounds (1) and (5) required concentrations of 
more than 50 µM to elicit cytotoxicity on MCF-7 and MDA-MB-231 
 
Paucinone H (4) was found to be actively inducing cell death in MDA-MB-231 at 20 µM 
concentration, 48 hours after treatment when compared with untreated control cells (Fig 2). We 
also noticed that paucinone H (4) had cytotoxic effects on MCF-7.  
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Table 4: Growth inhibitory effects of novel benzophenones from Garcinia paucinervis. 
Each of the cell lines under study were treated with novel benzophenones at 
concentrations: 5,10, 20, 30, 40, 50, 100 and 200 µM respectively for 48 hours. A WST 
assay was performed to measure cell viability. Results were analyzed using Graph Pad 
Prism (v 6.01) and found to be statistically significant (P ≤ 0.05) 
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Paucinone G (3) also showed some capacity to induce cell death. But none of the other 
paucinones tested were as effective as paucinone H on the panel of cell lines. Interestingly we 
noticed that paucinone H at IC50 concentrations caused apoptotic bodies characterized by nuclear 
chromatin condensation and cellular shrinkage as shown in Figure 14. Condensation of nuclear 
chromatin, membrane blebbing and cellular shrinkage have been reported to be hallmarks of 
apoptosis (Vermes et al., 2000) 
 
Figure 13: Growth inhibitory effects of paucinone H on MDA-MB-231. Images a, b, c, d, e and f 
denote control, 5, 10, 20, 40 and 100 µM concentrations of paucinone H, 48 hours after treatment. 
Magnification: 10X. Scale bar = 10µm 
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Figure 14: Growth inhibitory effects of paucinone H on MDA-MB-231, SKBR-3 and MCF-7. 
Paucinone H was the most potent among the novel benzophenones isolated from Garcinia 
paucinervis. Images a, b and c show cytotoxicity of paucinone H on MDA-MB-231, SKBR-3 and 
MCF-7 48 hours after treatment with 20 µM paucinone H. Red arrows indicate dead cells. 
Magnification: 10X. Scale bar = 10µm 
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Paucinone H causes an increase in apoptosis in MDA-MB-231 cells 
Since our cytotoxicity studies revealed that paucinone H was effective in inducing cell death in 
MDA-MB-231 cells at IC50 concentrations and MDA-MB-231 is a basal subtype of triple 
negative breast cancer, we wanted to understand if the mechanism of action involves apoptosis. 
The use of Propium iodide to access cell death has been reported earlier (Vermes et al. 2000). A 
simple apoptosis assay using Propium iodide was used to identify increase in apoptotic cells after 
treatment with paucinone H (4) at IC50 concentration. To show a dose responsive increase in 
apoptosis, cells were also treated with concentrations 5 and 20 µM and compared against the 
control. The fluorescence emitted by Propium iodide was captured using a live cell imager with 
fluorescent filter. Each treatment well was imaged thrice and the percentage increase in apoptotic 
cells was calculated.  A dose dependent increase in apoptosis was observed and the percentage of 
cells undergoing apoptosis increased by 50% after treatment with 20 µM paucinone H (4) in 
comparison with the control (Figure 14). All the hallmarks of apoptosis such as membrane 
blebbing, cellular shrinkage and nuclear condensation were prominent at this concentration. This 
is particularly interesting since breast cancer cells such as MDA-MB-231 with basal 
characteristics have been shown in the past to be responsive to drugs that cause DNA damage 
(Kalimutho et al., 2015)  
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Figure 15: Increase in the percentage of dead cells, 48 hours after treatment with paucinone H 
on MDA-MB-231. Images a, b and c represent Control, paucinone H 5 and 20 µM respectively 
are shown here. Results shown here are from three images per well per concentration. Average 
fluorescence relative to control was used to calculate percentage of apoptotic cells. 
Magnification: 10X. Scale bar = 10 µm. Statistical significance: P ≤ 0.01 
 
Decrease in the expression of mitotic marker phospho-histone 3 in MDA-MB-231 cells after 
treatment with paucinone H 
Mitotic activity is a key factor that is used in histological grading of breast carcinomas (Elston 
and Ellis 1991; Veras et al., 2009; Cui et al., 2015). One of the major constituents of chromatin is 
Histone H3. Phosphorylation of Histone H3 marks the initiation of mitosis (Hendzel et al., 1997; 
Perez-Cadahia et al., 2009). The use of phospho-histone 3(PH3) as a prognostic marker for 
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proliferation in triple negative breast cancer has been discussed earlier (Skaland et al., 2009; 
Klintman et al., 2013). 
 
 
Figure 16: Paucinone H induces a reduction in mitotic marker phospho-histone 3 at half IC50 
concentration within 24 hours after treatment on MDA-MB-231 cells. Images a and b show 
control and paucinone H 10 µM respectively after immunostaining for mitotic marker phospho-
histone 3. Blue nuclei denote DAPI. Magnification =10X. Results shown here are representative 
of two independent experiments with triplicate. Statistical significance: P ≤ 0.05 
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The prognostic value of phospho-histone 3(PH3) and the underlying link to prognosis in patients 
with a low PH3 index has also been reported (Skaland et al., 2007). In this context, we analyzed 
the expression of phospho-histone 3 in MDA-MB-231 cells after treatment with paucinone H at 
10 µM concentration. A significant reduction (50%) in the percentage of mitotic cells was 
observed within 24 hours after treatment (Figure 16). The experiment was repeated twice with 
triplicate and the percentage decrease in mitotic cells were estimated relative to control. Changes 
in PH3 has been proven to be useful in estimating mitotic activity in tumors, paucinone H could 
be a useful agent in inducing a decrease in mitotic activity even in solid tumors (Cui et al. 2015; 
Ginter et al., 2016). Also, the expression levels of PH3 helps in the evaluation of mitotic 
inhibitors in early stage drug development (Sun et al., 2012) 
 
Inhibition of migration in MDAM-MB231 cells post treatment with paucinone H 
TNBC is known to be one of the most metastatic types. Recurrence could often be attributed to 
metastasis (Kalimutho et al. 2015). To test if paucinone H can arrest migration, a scratch assay 
(wound healing assay) was performed. Wound closure was monitored for 48 hours and bright 
field images of the wound were captured. Each treatment had two replicates and the experiment 
was repeated twice. Migration of cells was calculated as the rate of wound closure relative to 
control. Wound width was normalized across all the wells to account for a wider scratch in the 10 
µM treatment well. A significant reduction in migration was observed in cells treated with 
paucinone H at a concentration of 10 µM (Figure 16). Continued imaging up to 3 days showed 
that a completely closed wound in the control well as opposed to the treated well which showed 
significant anti-migratory effects. 
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Figure 17: Anti-migratory effects of paucinone H on MDA-MB-231 cells. Images were recorded 
48 hours after treatment. Control and paucinone H 10 µM are shown here. White lines indicate 
the boundaries of the wound. Red arrows indicate cells (wound closure) in the control well. 
Results presented here are from two individual experiments with duplicates for each treatment. 
Statistical significance: P ≤ 0.01. 
Bright field imaging was continued past 48 hours to find the time taken for the control well to 
close completely. At 96 hours, the control well closed completely whereas the well with 10 µM 
paucinone H did not.  
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3.3 Discussion 
In this study, the activity of novel benzophenones isolated form Garcinia pacucinervis were 
presented for the first time across three different cell lines with varying receptor statuses. Since 
one of the compounds - paucinone H exhibited significant cytotoxicity on MDAM-MB-231, 
identifying the mechanism of action of Paucinone H was the next step. While were able to 
observe significant anti-proliferative and anti-migratory effects of paucinone H on MDA-MB-
231, further analysis into the downstream targets that elicit these responses would be the future 
direction for a more comprehensive study. Although benzophenones have been proven to be 
effective at modulating multiple anti-cancer pathways, their unique chemistry also comes with a 
challenging isolation process, since most of them are isomers. Previously, our lab has focused on 
the identification, isolation and purification of benzophenones from Garcinia xanthochymus 
(Baggett et al. 2005). However, since the compounds reported in this study were isolated from an 
endangered medicinal species, sample collection for a massive isolation process was impossible. 
Thus, compound availability was a limiting factor in our study. However, future studies 
involving this compound could utilize chemical synthesis methods which would help scaling up 
synthesis, that in turn would address the issue of compound unavailability.  
Once this is accomplished, future studies could involve study of specific pathways that could be 
modulated by paucinone H in order to elicit anti-proliferative effects. STAT-3 could be a good 
pathway of choice given that the role of STAT-3 in cell migration has been reported previously 
in MDA-MB-231 (Xing et al., 2015). A recent study has reported the use of xanthones from 
Garcinia xanthochymus in the inhibition of intracellular STAT-3 phosphorylation in MDA-MB-
231 cells. Given that benzophenones are chemically different from xanthones, this could be a 
particularly exciting avenue to focus, since a member of the benzophenone class was reported to 
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be potent against colon cancer cells that developed resistance to xanthones and other 
conventional antitumor agents (Kan et al. 2013). The second pathway worth exploring would be 
PI3K/AKT/Mtor, due to its underlying link in regulating cell proliferation, motility and the fact 
that it is often over expressed in TNBC patients (Janku et al., 2012). While the inhibitory effects 
of structurally similar benzophenones on Mtor pathway has been reported in colon cancer cells, 
no such study exists on triple negative breast cancer and benzophenones (Einbond et al. 2013). 
Given that the need for a targeted therapy to decrease mortality rates due to triple negative breast 
cancer is the need of the hour, this study would serve as a reference for researchers in 
understanding the use of benzophenones and their possible pathways of action in triple negative 
breast cancer. This in turn could lead to the use of paucinone H by itself or in synergy with 
existing chemotherapeutic drugs in the treatment of triple negative breast cancer. 
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Chapter 4: Conclusion 
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The increasing number of TNBC cases and the lack of targeted therapies, makes TNBC one of 
the major focus areas of the research community. Currently there are about 439 clinical studies at 
various stages, that explore the use of existing and new strategies to treat 
TNBC(ClinicalTrials.gov 2017). Novel benzophenones from Garcinia paucinervis, especially 
paucinones G and H were effective against triple negative breast cancer (TNBC). Given the 
nature of TNBC and the need for a targeted agent against TNBC, future studies could utilize 
novel benzophenones presented in this study in the development of a targeted therapeutic agent. 
The limited availability of the bioactive compound (paucinone H) is an issue that needs to be 
addressed before commencing future studies. Garcinia paucinervis has also been declared as an 
endangered species and been placed in the IUCN list of threatened species (Sun 1998). This 
poses a challenge for sample collection. In addition, paucinones were isolated from the seed 
extract of Garcinia paucinervis and paucinones H and G appeared as isomers. In an earlier study, 
the Kennelly lab reported that guttiferone E is more bioactive in than  its isomer xanthochymol 
(Protiva et al. 2008). Guttiferone E has a double bond between C32 and C33 whereas, 
xanthochymol has a double bond between C33 and C34 (Acuna et al. 2010). This could explain 
the reason for greater cytotoxicity and the corresponding anti-apoptotic activity of guttiferone E. 
Similarly, in the present study paucinone H which lacks a hydroxy group was comparatively 
more bioactive than its isomer. One of the challenges of working with isomers is their separation 
from their structurally similar counterparts. Although separation was accomplished as mentioned 
by (Li et al. 2016a), the use of UPLC QTOF was inevitable in this process. Given these 
limitations, care was taken to design experiments which would help give a basic insight into the 
possible pathways that paucinone H is capable of modulating in TNBC. The cell line that was 
used in all these experiments was MDA-MB-231. In addition to inducing significant cell death at 
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20µM concentration, paucinone H was also able to cause significant decrease in expression of 
phospho-histone 3 (a mitotic marker) at half IC50 concentration. Paucinone H also caused 
significant inhibition of migration of cells in a scratch assay. 
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Chapter 5: Future studies 
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To understand the ability of paucinone H to induce cytotoxicity in other TNBC cell lines, MDA-
MB-468 was also used as part of the study. In contrast with MDA-MB-231 which has wild type 
PI3K, MDA-MB-468 is PTEN negative and has high epidermal growth factor receptor (EGFR) 
(She et al., 2008). This difference between the selected cell lines could later help figure out if the 
mode of action of paucinone H is through PI3K pathway. During the initial studies to screen for 
activity of paucinone H on MDA-MB-468, it was noticed that at 20 µM cell death was not as 
pronounced as in MDA-MB-231. 
 
Studies from the Kennelly lab have shown that three Garcinia derived benzophenones – 
xanthochymol, guttiferone E and guttiferone H caused growth inhibition on a panel of colon 
cancer cell lines (Einbond et al. 2013). The mode of action of these benzophenones, especially 
for xanthochymol was partly stated to be via activation of endoplasmic stress response and 
inhibition of mammalian target of rapamycin (mtoR) cell survival pathway. Especially mTOR 
C2, since the involvement of ER IP3R was reported. Due to the limitations mentioned earlier, the 
possibility of inhibition of mTOR by paucinone H was not studied. This could well be a future 
study 
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Figure 18: Growth inhibitory effects of paucinone H on MDA-MB-468. Images a, b, c, d, e and 
f denote control, 5, 10, 20, 40 and 100µM concentrations of paucinone H, 48 hours after 
treatment. IC50 was estimated to be 20 µM. Magnification: 10X. Scale bar = 10µm 
 
 
PI3K/AKT/mTOR is the essential signaling pathway involved in survival, cell proliferation, 
metabolism and regulation of motility (Gonzalez-Angulo and Blumenschein 2013). PI3K is one 
of the targets explored in the development of therapeutics against TNBC (Ciruelos Gil 2014). 
Almost 60% of TNBC patients show over activation of the PI3K pathway, mostly with a 
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mutation or deletion of PTEN and loss of heterozygosity at the INPP4B locus (Shah et al., 2012). 
AKT is an important downstream target of the PI3K pathway and it regulates proliferation, 
growth, cell survival, proliferation apoptosis and glycogen metabolism (Ma et al., 2016). mTOR 
(The mammalian target of rapamycin) – another downstream component of the PI3K/AKT 
pathway is a serine/threonine kinase, occurring as two distinct complexes – mTOR C1 and 
mTOR C2 (Massihnia et al. 2016). mTOR C1 is a growth regulator that is composed of mTOR, 
Raptor, GβL and DEPTOR while mTOR C2 is composed of mTOR, Rictor, GβL, Sin1, 
PRR5/Protor-1, and DEPTOR (Dowling et al., 2010). Since previous studies with xanthochymol 
a Garcinia derived benzophenone have pointed out to the possibility of xanthochymol altering 
mTOR C2, future studies with paucinone H could be focused in this direction. 
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Appendix A: Comparative UPLC-QTOF-MS-based metabolomics and bioactivities 
analyses of Garcinia oblongifolia  
Additional projects on the in-vitro activity of Garcinia spp. that resulted in two peer reviewed 
publications are discussed in Appendices A and B respectively. One of these studies involved 
analyzing the activity of the vegetative organs of Garcinia oblongifolia against breast cancer. 
Although the medicinal value of Garcinia species is well studied, there were no reports on their 
effects against breast cancer. This study involved, comparative metabolic profiling and 
bioactivity analysis of vegetative organs of Garcinia oblongifolia. All vegetative organs used in 
the study were collected, stored and extracted as described previously (Li et al., 2016b). Briefly, 
leaves and branches collected were air dried, while fruits were freeze dried before beginning the 
extraction process. The dried samples were then extracted with 80 % methanol, concentrated in 
vacuo and stored at -20◦C until use. UPLC-QTOF-MS and MSE followed by heatmap analysis 
helped identify the metabolite profile of the extracts under study. This was followed by use of 
bioassays to understand cytotoxicity of the studied extracts. The cytotoxic effects of plant 
extracts was evaluated in estrogen receptor positive breast cancer, using MCF 7 cell line. Human 
MCF 7 cells were cultured in DMEM Glucose medium (Gibco, BRL Life Technologies, Inc., 
Rockville, MD) and maintained in an incubator at 37◦C and 5% CO2. Cell growth media was 
supplemented with 10% FCS and 100 µl penicillin/ streptomycin.  
 
Cytotoxicity of the extracts under study was evaluated using a WST-12-(4-iodophenyl)-3-(4-
nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium, monosodium salt assay. A concentration of 
12, 000 cells per well were seeded in 96 well plates after which they were treated with branch, 
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fruit, leaf or seed extract respectively. Cells were treated at concentrations: 31.25, 62.50, 125, 
250, 500 and 1000 µgml-1 , 24 hours after plating. An untreated well and a well with 0.01% 
DMSO were used as controls.  
 
 
Figure 19. 1) Morphological changes in MCF-7 cells after treatment with Garcinia oblongifolia 
extracts. Images a, b, c and d represent control, branch, fruit and leaf extract at 500 µgml-1 
respectively. Mild vacuolization observed after treatment with leaf extract and extensive 
vacuolization observed with the branch extract are marked with a triangle and an asterisk 
respectively. A dead cell is marked in figure b with a black arrow. Graphs 1, 2 and 3 show the 
1 
2 3 
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growth inhibitory effects of the branch, leaf and fruit extracts on MCF-7 cells 24 hours after 
treatment. Magnification:10X; Scale bar = 100 µm 
24 hours after treatment, the contents in each well were removed and washed thoroughly with 
serum free media. This step was followed by the addition of 150 µl of 10% WST solution. The 
96 well plates were then wrapped in aluminum foil and incubated for an hour.  Absorbance was 
read at 440 nm using a Spectra Max (340 PC) plate reader. The percentage inhibition relative to 
control was calculated from the average absorbance values. All experiments were performed in 
triplicate. Results were then analyzed using Graph Pad Prism.  
Changes in cell morphology as shown in Figure 19.1 were captured using a high objective fully 
enclosed inverted microscope (Zeiss Axio Observer, Thornwood, NY). Images were captured up 
to 48 hours after treatment. Controls used were the same as that of the bioassays. The results 
revealed that the branch extract was the most bioactive in comparison with the leaf and fruit 
extracts (Figure 19 Graphs 1, 2 and 3).  
 
The cytotoxicity results observed, coincided with principal component analysis (PCA) of the 
metabolite profiles of different vegetative organs studied. A total of 12 compounds which 
included 10 xanthones and 2 biflavonoids were unique to the branch extract. In contrast, leaves 
showed the least amount of biflavonoids and fruits were low in xanthones. Therefore, the higher 
activity of branch extract in cytotoxicity assays could be attributed to the high concentration of 
xanthones. The approach handled in this study proved to be a time consuming and effective 
screening strategy for bioactive constituents from medicinal plant extracts.  
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Appendix B: UPLC-QTOF-MS guided dereplication of an endangered Chinese Garcinia 
species to identify cytotoxic benzophenones in triple negative and other breast cancer cell 
lines  
This study describes a new strategy in which UPLC-QTOF-MSE technique was used to identify 
benzophenone derivatives using characteristic fragment ions. Garcinia species has previously 
been studied by our group to contain several bioactive compounds mostly belonging to the class 
of benzophenones(Baggett et al. 2005; Einbond et al. 2013). Several other Garcinia members 
such Garcinia xanthochymus, Garcinia kola, Garcinia atroviridis, Garcinia mangostana, 
Garcinia bractea and Garcinia celebica have been studied in several in-vitro assays and in-vivo 
models (Suksamrarn et al., 2006; Subarnas et al. 2016; Mohamed et al. 2017; Tan et al., 2017). 
But this is the first study that reported Garcinia paucinervis – an endangered species for its 
cytotoxicity and possible mechanisms of action against multiple breast cancer cell lines 
irrespective of their receptor status 
 
UPLC-QTOF-MS guided targeted isolation of unidentified compounds, resulted in the 
identification of five novel compounds that belong to the class of benzophenones, paucinones E -
I. Their structures were elucidated using MS, NMR and ECD spectroscopy as described in our 
recent publication (Li et al. 2016a) 
 
All five compounds were treated on 3 different breast cancer cell lines with varying receptor 
status to screen for their activity in bioassays. MDA-MB-231, MCF-7 and SKBR-3 were the cell 
lines used in this study. Cells were cultured in DMEM glucose medium (Gilbco, USA) 
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supplemented with 10% fetal calf serum and 100 µL of antibiotics (penicillin and streptomycin). 
SKBR3 cells were cultured in DMEM F12 glutamine medium supplemented with 10% fetal calf 
serum and 100 µL of antibiotics (penicillin and streptomycin). All cell lines were maintained at 
37 °C in an incubator with 5% CO2. 
 
An in-vitro assay was done to determine the cytotoxicity of the compounds on the cell lines 
under study. All compounds were dissolved in DMSO and diluted with required volumes of 
respective cell culture media before each treatment. To determine the cytotoxicity effects of test 
compounds on the three cell lines used in this study, exponentially growing cells (12 × 103 
cells/well) were seeded in 96 well multitier plates. After 24 h, each test compound was added to 
each cell line used in his study. Concentrations of the compounds studied ranged from 5 to 200 
µM. Doxorubicin was used as a positive control. After 48 hours of treatment, a cell viability 
assay (WST) was performed. Each well was washed twice with serum-free medium followed by 
the addition of a 10% WST solution. This solution (150 µL) was then added to each well. The 
plates were wrapped in aluminum foil and incubated for 1 h, their absorbance was then read at 
440 nm using a Spectra Max plate reader. Each experiment was performed in triplicate. Average 
absorbance and the percentage inhibition relative to control were calculated. The results were 
analyzed using Graph Pad Prism Software (v 6.01)(Graph Pad Software, San Diego, CA, USA), 
and IC50 values were estimated. Doxorubicin was used as the positive control in these studies. A 
schematic representation of the study set up is shown below in Figure 20. 
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Figure 20: A schematic representation of the study set up. 
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Paucinone H was identified to be the most bioactive compound. Although the overall activity 
level was similar around the IC50 range (19.05 µM), the compound was particularly active in 
triple negative cell line MDA-MB-231 and estrogen receptor positive cell line MCF-7. We later 
studied the possible targets of this compound and its mode of action in triple negative breast 
cancer cell lines 
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